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1 Introduction 
According to the National Human Genome Research Institute,[1] there are known 
over 6000 disorders, e.g. cystic fibrosis, sickle-cell anemia, and Huntington's dis-
ease, which are classified as genetic diseases. On the example of cystic fibrosis, 
which is one of the most frequent fatal inherited diseases having its onset in child-
hood:[2] about 30 000 people in the United States suffer from the disease, caused by 
mutations in a single gene - the Cystic Fibrosis Transmembrane Regulator (CFTR) 
gene. Whereas most treatments still focus on alleviating the symptoms of a disease, 
the greatest hopes are pinned on gene therapies. Gene therapy is a treatment 
method working on a gene level: replacement of missing or defective genes with 
correct ones, inactivating a mutated gene, or introducing a new gene. Although in 
2015 there were 167 gene therapy clinical trials approved worldwide,[3] the tech-
nique evokes many safety and efficiency concerns. Introducing genes to the cells is 
challenging and may bear risks for many reasons: DNA has to be transported into 
the nucleus; can integrate into the genome, causing insertional mutagenesis; and 
the resulting expression is enduring with only limited control.  
1.1 Messenger RNA (mRNA) 
In the process of protein expression from a gene, an important role is played by an 
intermediate molecule, namely messenger RNA (mRNA). The information about 
certain genes (proteins) stored in DNA is replicated to a single-stranded mRNA in 
the transcription process. In eukaryotic cells, the transcript is produced by three 
different types of RNA polymerase[4] and, after processing including the addition of 
a 5’ cap and poly-A tail at the 3’ end as well as splicing, the mature, single-stranded 
transcript is transported to the cytoplasm. Then the biological protein synthesis 
takes place, using the information in mRNA as a template. This process (translation) 
occurs in molecular machineries called ribosomes with the participation of riboso-
mal RNA (rRNA) and transfer RNA (tRNA). When its role is fulfilled, mRNA is degrad-
ed, which allows the cells to control the protein synthesis level. Eukaryotic mRNAs’ 
half-lives range from several minutes to several days.[5]  
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Influencing the protein production process from the transcript level opens a com-
pletely new possibility to treat gene disorders with benefits of: avoiding the risk of 
insertional mutagenesis, the necessity to deliver the nucleic acid to the cytoplasm 
only, and the transient translation of proteins produced in the patient’s cells.  
1.2 Chemically modified mRNA and transcript therapies 
The greatest obstacles on the way from mRNA discovery to its therapeutic applica-
tion have so far been the molecule’s limited stability and strong immunogenicity.[6] 
As it has been described, these limits could be overcome by simple nucleoside mod-
ifications, which suppress the immune-stimulatory effects by decreased activation 
of the innate immune system sensors, e.g. Toll-like receptors, and immune cells, 
e.g. dendritic cells.[7] Moreover, chemical modifications such as replacement of uri-
dine with pseudouridine can facilitate protein translation by diminishing activation 
of RNA-dependent protein kinase (PKR).[8] Further exploration of the chemically 
modified mRNA (cmRNA) showed that substitution of only 25% of uridine and cyti-
dine with 2-thiouridine and 5-methyl-cytidine not only decreases activation of the 
immune system in vivo but also significantly escalates levels of reporter as well as 
physiologically functional protein.[9] With such improvements, mRNA-based thera-
peutics have many advantages: pharmaceutical safety, rapid and transient transla-
tion profile, in situ generation of proteins, and the possibility of repeated dosing. 
Overall, these mRNA characteristics create an opportunity of a wide range of medi-
cal applications. Starting from examples of metabolic diseases: it has been shown 
that mRNA coding for mouse erythropoietin (mEpo) led to increase in hematocrit in 
treated mice.[9] Another therapeutic potential of chemically modified mRNA lies in 
the treatment of genetic disorders and has been described in a model of a heredi-
tary, lethal lung disease - congenital surfactant protein B (SP-B) deficiency. Repeat-
ed, aerosol application to the murine lungs restored 71% of the wild-type SP-B 
translation and prolonged the average life span of the animals.[9] A further possibil-
ity using mRNA is regenerative medicine, e.g. bone healing. Already two weeks after 
orthotopic administration of cmRNA coding for human bone morphogenetic protein 
2 (hBMP-2), an accelerated bone regeneration in rat bone defects was observed.[10]  
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1.3 Delivery challenge in transcript therapies 
The direct delivery of mRNA into cells is hampered by its highly anionic character 
that largely prevents a passage across cell membrane. To fulfil its function, the 
mRNA has to reach the cytosolic compartment of a cell. An additional barrier is rep-
resented by the ubiquitous presence of RNases. A potential solution could be local 
delivery to the target tissue by direct injection (e.g. intramuscular injection) but 
most organs are not easily accessible by this route of administration. For example, 
in order to treat metabolic liver diseases, mRNA must enter liver hepatocytes, 
which are only accessible from the blood stream. However, as any drug, mRNA in-
troduced into the body via intravenous injection has to overcome numerous barri-
ers on its route to the target cell: interaction with blood and serum components 
and cells of the immune system, among others. Unspecific interactions could lead to 
unwanted side effects such as e.g. blood coagulation and enhanced clearance. Fur-
thermore, once the target tissue is reached, mRNA needs to cross the cellular 
membrane and enter the cytoplasm. To address all these challenges, a properly 
designed delivery system is necessary. It has to meet certain requirements such as 
efficient encapsulation of mRNA, protection from degradation and undesired inter-
actions in the blood stream, delivery to the tissue of interest, possession of effective 
cell penetrating properties, the endosomal escape ability, and the final release of 
the mRNA into the cytoplasm.  
1.4 Cellular uptake and endosomal escape 
The cell membrane, consisting of a phospholipid bilayer with embedded proteins, is 
selectively permeable to small molecules. However, macromolecules cannot easily 
cross the membrane mostly due to their large size. In addition, mRNA is too hydro-
philic and negatively charged to efficiently diffuse on its own across the cell mem-
brane. Thus, an important barrier for an mRNA-carrier complex is association with 
the membrane and subsequent cellular uptake. The main mechanism of macromo-
lecular drug complex internalization into the cells is the vesicular uptake by endocy-
tosis.[11–13] So far, numerous mechanism of endocytosis have been described,[14,15] 
as schematically depicted in Figure 1.1.  
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Figure 1.1.  Different cellular uptake pathways in nonviral  gene delivery. [ 13 ]  
 
Once a complex enters the cell via endocytosis, it is trapped in intracellular vesicles. 
If it does not escape from endosome, it will be transported from early to late endo-
some and finally be degraded along the lysosomal pathway.[16] Endosomal escape 
requires membrane destabilization, which could be obtained e.g. in an acidification-
dependent manner.[17] One hypothetical mechanism of endosomal escape of 
nonviral carriers is the proton sponge effect, firstly proposed by Jean-Paul Behr.[18] 
According to this theory, cationic vehicles, which are only partly protonated at neu-
tral, extracellular pH and possessing substantial buffering capacity below physiolog-
ical pH, may cause endosome swelling and rupture of the endosomal membrane 
through influx of chloride counterions and water.[19] Another assumed mechanism 
for cationic lipid-based complexes suggests rather disruption of the endosomal 
membrane by promoting the formation of nonbilayer lipid structures in combina-
tion with anionic phospholipids.[20] It has been reported that a pKa value between 
6.2-6.5 of cationic lipids exhibits a high correlation to their activity in vivo.[21]  
Finally, an efficient transfection process further requires dissociation of the mRNA 
from the carrier after reaching the cytoplasm. 
1.5 mRNA delivery systems 
In general, mRNA carriers can be divided into viral and nonviral vectors.[22,23] De-
spite some potential advantages of viral vectors, i.e. expression and replication of 
some RNA viruses localized in the cytoplasm and a capacity to express large 
amounts of protein in a broad range of different hosts,[24] a high risk of carcinogen-
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esis, immune side effects, and difficulty of vector production limit the development 
of viral delivery systems.[25] A variety of promising nonviral carriers has been de-
scribed for gene-based approaches, mostly lipoplexes and polyplexes. The basic 
principle in mRNA delivery involves the use of cationic polymers or lipids, resulting 
in complexation of the negatively charged nucleic acid via electrostatic interactions 
as well as further interactions with cell membranes. 
1.5.1 Polymers 
Based on experiments with widely used polymers for nucleic acid delivery, e.g. pol-
yethylenimine (PEI) and poly(L-lysine) (PLL, see Figure 1.2a-b), it appeared that, spe-
cific to polymeric particles, binding strength between the mRNA and polymer is crit-
ical for translation efficiency.[26] Whereas transfection with PEI 25 kDa or PLL 54 kDa 
did not lead to any translation in vitro, smaller molecular weight polymers, 2 kDa 
and 3.4 kDA, significantly increased their activity in the presence of chloroquine, an 
agent of endosomolytic activity.  
In comparison to PEI, polycations with histidine and polylysine residues (HIS RPCs) 
proved to enable efficient translation.[27] Transfection with histidine-rich RCPs me-
diated high levels of green fluorescent protein (GFP) in prostate cancer cells (PC-3), 
achieving as much as 97% positive cells in contrast to 33% transfected with PEI.  
With a view toward delivery of mRNA-based vaccines, nanoparticles based on 
poly(β-amino ester) and coated with a phospholipid bilayer were developed.[28] 
They led to successful transfection of dendritic cells in vitro, as well as reporter 
mRNA delivery after intranasal administration in mice. The design of described par-
ticles included surface binding of mRNA via electrostatic interactions, reduction of 
the toxicity by reduced interaction with the lipid bilayer and promotion of endoso-
mal escape by pH-responsive poly(β-amino ester). 
In another study, the effect of PEGylation on the binding and transfection efficiency 
of polymers was investigated. Two types of polymers were analyzed, linear PEI and 
poly-N,N-dimethylaminoethyl methacrylate p(DMAEMA) (see Figure 1.2c), demon-
strating that PEGylation improved mRNA binding, particle formation, and transfec-
tion efficiency as compared to their unmodified counterparts.[29] Additionally, en-
hanced endosomal release achieved by influenza-peptide 7 (an endolysosomal re-
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lease peptide) further improved transfection efficiency. However, side-by-side 
comparisons of mRNA and pDNA complexes led to contradictory results, which is a 
proof that delivery systems require tailor-made design for each type of nucleic acid.  
Expanded knowledge about factors required for effective and safe delivery systems 
allowed to develop more complex carriers designed to enhance intracellular deliv-
ery of mRNA. Recently, triblock compolymers consisting of a cationic dimethylami-
noethyl methacrylate (DMAEMA) mediating mRNA condensation, a hydrophilic 
poly(ethylene glycol) methyl ether methacrylate (PEGMA) which enhances complex 
stability and biocompatibility, and a pH-responsive endosomolytic copolymer of 
diethylaminoethyl methacrylate (DEAEMA) and butyl methacrylate (BMA) which 
facilitate cytosolic entry were described (see Figure 1.2d).[30] The order of these 
blocks as well as PEGMA length were varied to find the optimal combination for 
mRNA transfection efficiency. As a result, polyplexes of DMAEMA-PEGMA-DEAEMA-
co-BMA exhibited the greatest stability and efficacy in two immune cell lines 
RAW264.7 macrophages and DC2.4 dendritic cells (77 and 50% of transfected cells, 
respectively).  
 
Figure 1.2.  Chemical  structures of  polymers described for mRNA delivery: a)  polyethylenimine (PEI) ,  
b)  poly(L-lysine) (PLL) ,  c)  poly-N,N-dimethylaminoethyl  methacrylate (p(DMAEMA)),  and 
d) poly(DMAEMA-PEGMA-DEAEMA-co -BMA).  
 
d) 
c) b) a) 
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How even subtle changes in the carrier structure can influence transfection efficien-
cy, was described in one example of N-substituted polyaspartamides with varied 
numbers of side chain aminoethylene repeats.[31] A clear correlation between the 
number of aminoethylene repeats and the translation level was found. Polyplexes 
with odd number of repeats (PA-Os) showed an increase in efficiency compared 
with those with even number of repeats (PA-Es). Thorough investigation of this ef-
fect revealed that two factors i) endosomal escaping capability and ii) stability in the 
cytoplasm play a critical role in the transfection process. Despite high endosomal 
escape efficacy of PA-Es, their insufficient cytoplasmic stability led to rapid mRNA 
degradation and, hence, lower transfection efficiency. In contrast, PA-Os stability 
overcame the limited endosomal escape capability, resulting in more sustainable 
translation. Interestingly, the same constructs comprising pDNA instead of mRNA 
showed the opposite pattern, which again indicate that each optimization and fine-
tuning of the carrier needs to be tailored for the nucleic acid of interest. 
1.5.2 Lipids 
Since 1989, when a synthetic cationic lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-
trimethylammonium chloride (DOTMA) was reported to transfect human, rat, mu-
rine, Xenopus and Drosophila cells with mRNA coding for luciferase,[32] the field of 
lipid nanoparticles has gained a great interest in mRNA delivery. Despite the fact 
that its toxicity restricted the clinical development, DOTMA remained a common 
component of lipoplexes. Another widely used cationic lipid is DOTAP (1,2-dioleoyl-
3-trimethylammonium-propane (chloride salt)), which is efficient in both in vitro 
and in vivo applications.[26,33,34] However, positively charged lipoplexes can be quick-
ly removed from the systemic circulation, which strongly hampers their efficiency in 
vivo. To overcome this obstacle, it is common in nucleic acid delivery to coat lipid 
nanoparticles with poly(ethylene glycol) (PEG),[35,36] which improves carrier stability 
in blood and prevents aggregation.[37,38] On the other hand, the use of PEG may 
have undesirable effects such as interfering with the cellular uptake and following 
intracellular processes.[39,40]  
Even though some lipid delivery systems for mRNA vaccination have been described 
and are currently in clinical testing,[41,42] no carriers for mRNA-based therapies exist 
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on the market so far. Since lipid-based carriers represent a potentially efficient de-
livery platform, their thorough development might warrant detailed investigation 
for future applications in transcript therapies. 
1.6 Lipid nanoparticles as a multicomponent system 
As mentioned in the previous chapters, mRNA binding as well as interactions with 
the cell membrane are achieved by the use of a cationic lipid or polymer. In addi-
tion, in order to increase complex stability in the blood circulation, a PEG-coating 
could be applied. To improve particles stability and transfection efficiency even fur-
ther, additional components can be included in the lipoplex. 
1.6.1 Cationic lipids 
Since cationic lipids represent the most critical part of lipoplexes for efficient nucleic 
acid delivery, the main emphasis is placed on finding the most effective and bio-
compatible structures both in vitro and in vivo. With the purpose of gene silencing 
via systemic delivery of siRNA, a novel synthetic approach was developed.[43] Previ-
ously, conventional lipid synthesis methods limited the ability to screen a high 
number of diverse structures. The rapid synthesis of a large library of over 1,200 
lipid-like compounds (lipidoids) was enabled by performing reactions in the absence 
of solvent or catalysts, which eliminated the necessity of protection and deprotec-
tion steps or purification. Briefly, the library was generated by the conjugate addi-
tion of alkylacrylates or alkylacrylamides to low molecular weight oligoalkylamines 
comprising primary or secondary amines. After screening their ability to deliver siR-
NA in vitro, the top performing lipidoids were found to follow some structural rules 
which were important regarding delivery efficiency including most preferably an 
amide linkage, more than two alkyl tails, tail length in the range of 8–12 carbons, 
and one not fully modified, secondary amine. Resulting lipidoid formulations of po-
tent silencing activity proved to be efficient in three distinct species, including non-
human primates. Worth mentioning, the formulations contained, apart from lipid-
oid and siRNA, a PEG-lipid and cholesterol. This strategy created a foundation for 
new material development and was further improved regarding delivery efficacy. 
Another class of lipidoids, composed of polar head groups containing amines and 
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nonpolar hydrocarbon tails, was reported to facilitate gene silencing at significantly 
lower doses than any siRNA carriers before.[44] Similar as described above the syn-
thesis method included a one-step reaction of epoxides with amines, required no 
purification and obtained lipids could be used directly for in vitro screening. An im-
portant conclusion from the study was that an optimized combination of amine 
group and tail length is required for nucleic acid delivery efficacy. For in vivo appli-
cation, lipid formulations included additional distearoyl phosphatidylcholine (DSPC), 
cholesterol, and a PEG-lipid to increase particle stability. Importantly, no toxicity in 
mice was observed even several orders-of-magnitude above the efficacious dosage. 
The properties of a cationic lipid determining its high activity in the formulation 
were investigated with a large number of head group modifications to the lipids.[21] 
A clear correlation between the lipid pKa value and the silencing efficacy of the lipid-
siRNA complex in vivo was found, with an optimal pKa range of 6.2–6.5. Previously, 
it has been noted that permanently charged quaternary amine moieties in the hy-
drophilic head group region were less effective in vivo as compared to ionizable 
lipids.[45] It has been proposed that neutral or close to neutral lipoplexes will exhibit 
minimal undesired interactions with proteins or blood cells after systemic admin-
istration, thus increasing the chances of reaching the liver tissue. On the other 
hand, positive surface charge enables interaction and destabilization of the endo-
somal membrane, resulting in endosomal escape of a complex. These two, seeming-
ly contrary conditions, are fulfilled by ionizable lipids with pKa between 6.2 and 6.5, 
as they show minimum charge at physiological pH and maximum positive charge in 
the acidified endosomal compartment.[21] However, the presented data indicated 
that although an optimal pKa value is necessary, there are also other features such 
as the linker between the head group and the lipid tails, which can drastically affect 
the activity in vivo.  
It has also been proposed that amino lipids with a small headgroup can adopt in-
verted, nonbilayer structures, which are hypothesized to destabilize the endosomal 
lumen, resulting in efficient release of nucleic acid cargo into the cytoplasm.[20,45] In 
addition to headgroup structures, other functional elements (alkyl chain, linker) can 
affect the properties of lipidic carriers.[45] In an attempt to define structure-function 
relationships, Whitehead et al. analyzed different criteria of degradable lipidoids 
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from a generated library and their correlation to siRNA delivery capability in vivo.[46] 
Based on the findings, a second-generation library was developed, designed to-
wards potentially efficacious materials, following presumably critical structural 
rules. As a result, a set of four efficacy criteria predicting in vivo efficacy were estab-
lished: appropriate tail length (alkyl-acrylate of 13 carbon chain length), alkylamine 
containing at least one tertiary amine, at least three substitution sites, and a pKa 
value above 5.4. 
All of these discoveries contribute to the design of effective cationic lipids. This 
identified structure-function relationship represents a guideline for the design of 
future materials for nucleic acid delivery. 
1.6.2 The role of helper lipids 
The advanced lipid systems for siRNA delivery are usually composed of a cationic 
lipid/lipidoid, phospholipid, cholesterol, and a PEG-lipid. The knowledge about lipo-
plex structure could also help in understanding the exact role of helper lipids com-
monly used in the formulations. The classical model of lipid-nucleic acid complex 
(see Figure 1.3a) assumes a bilayer structure with a nucleic acid encapsulated in the 
aqueous interior.[47] However, recent cryo-transmission electron microscopy (cryo-
TEM) studies revealed a presence of electron-dense cores[48] instead of less dense 
aqueous cores.[49] A thorough structure characterization using multiple biophysical 
assays combined with computer modeling showed that encapsulated nucleic acid is 
bound to cationic lipid in the internal core, which also contains phospholipid and 
cholesterol, whereas the outer layer consists of a homogeneous PEG-lipid coating 
(see Figure 1.3b).[50] The results also suggest that nucleic acid is immobilized in in-
verted micelles, fully protected from enzymatic degradation. Additionally, a role of 
phospholipid (phosphocholine) in the four lipid component formulation was pro-
posed. Used in numerous lipid vehicles, it has been believed to contribute to parti-
cle stability. However, the obtained data suggested rather a role of charge mediator 
including forming ion pairs between the phosphate group of a lipid and the cationic 
lipid headgroup, whereas choline interacted with nucleic acid phosphates. Choles-
terol is hypothesized to be distributed homogenously in the core and surface, pre-
sumably facilitating the formation of the inverted hexagonal phase.  
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Figure 1.3.  A scheme of  a l ipid nanoparticle  (LNP)  with encapsulated nucleic acid: a) classical  mod-
el [ 46 ]  and b) nano-structured core model . [ 51 ]  
 
Cholesterol is a natural, essential component of lipid membranes, stabilizing their 
structure and maintaining fluidity. In some carriers developed for siRNA delivery it 
has been shown that by varying the ratio of cholesterol in the formulation different 
liver cell subpopulations can be targeted.[52] 
1.6.3 PEG coating 
In order to prevent aggregation and prolong circulation life time by creating stealth 
nanoparticles, a coating of a PEG-lipid is widely used in lipid-based delivery. Howev-
er, the thoughtful choice of a PEG-lipid type has a huge impact on the carrier activi-
ty. For instance, it has been shown that the lipid anchor length determines how long 
the PEG-coating remains associated with the particle. Longer anchors in PEGylated 
ceramides need more time to be dissociated, which prevents interactions with cells 
and extends particles circulation time.[53] On the other hand, complexes comprising 
long acyl anchors (PEG-DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 
C18 anchors) were rapidly removed after systemic administration as a consequence 
of an immune response to the PEG component.[54,55] This immunogenic response 
and resulting clearance can be avoided by using shorter anchors which rapidly dis-
sociate from the complex (i.e. PEG-DMG, 1,2-dimyristoyl-sn-glycerol, C14 
anchors).[51] The explanation behind these dependences is that a PEG-lipid is incor-
porated into a complex hydrophobically, and thus deshielding can be controlled 
relatively easy by changing its hydrophobic properties.[56] 
b) a) 
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1.6.4 Targeting ligands 
Even without any external ligands conjugated to them, lipid nanoparticles can natu-
rally target the liver via interactions with apolipoprotein (Apo) E, a natural serum 
protein.[57] The uptake of neutral lipoplexes by liver cells (hepatocytes) is enhanced 
by ApoE in vivo.[58] To target other tissues, the use of some exogenous ligands might 
be a necessity. Despite being efficient, ligands such as antibodies (or their frag-
ments) and peptides have some disadvantages, with high costs and difficulties in 
manufacturing, among others. Consequently, small molecule ligands, which are rel-
atively easy to synthesize and conjugate on the surface of lipid nanoparticle, repre-
sent a more promising approach for enhanced delivery to the target cells.[59,60] For 
example, to target the liver in an ApoE-independent manner, N-acetylgalactosamine 
(GalNAc), which binds with high affinity to the asialoglycoprotein receptor (ASGPR) 
present on the surface of hepatocytes, can be applied in the formulation.[59] Lung 
tumours and metastases can be targeted with a specific ligand such as anisamide, 
which interacts with sigma receptors.[61] Another described small molecule ligand, 
cardiac glycosides strophanthidin, stimulates endocytosis on binding to plasma 
membrane Na+/K+ ATPase and enhances uptake in a variety of cell types derived 
from different tissues.[60]  
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1.7 Aim of the thesis 
Transcript therapy based on chemically modified mRNA creates an opportunity to 
treat rare metabolic and/or genetic diseases that have had no cure until now, only 
options to alleviate the symptoms and improve the quality of patient’s life. Moreo-
ver, the versatility of this nucleic acid provides numerous other potential applica-
tions, e.g. bone regeneration or cancer therapy. The major hurdle that must be 
overcome before achieving the final goal of clinical application is the delivery pro-
cess. Despite some carriers described so far, the field is still in an early development 
stage. The complexity of the process is a challenge but in context with previous pro-
gress which has been made in the field of nucleic acid delivery, the critical factors 
that have to be taken into consideration in a design are continuously better defined. 
Importantly, even though delivery systems for other nucleic acids (pDNA, siRNA) 
have been investigated more thoroughly, mRNA vehicles need to be tailored to its 
unique molecular properties in context with the intended site of action. 
In this thesis, a lipid-based system has been chosen because of its known capability 
to mediate efficient cellular uptake. A multicomponent system consisting of a lipid-
oid for mRNA binding and interaction with cells, helper lipids improving particle 
stability and enhancing transfection process, as well as a PEG-lipid prolonging blood 
circulation, preventing aggregation and undesired interactions has been adopted as 
a starting point. The aim of this thesis was the optimization of such a formulation in 
context with the needs of mRNA for in vivo applications. The ultimate goals were:  
• formation of stable, monodisperse nanoparticles 
• high transfection efficiency obtained by effective cellular uptake and endo-
somal escape 
• low cytotoxicity 
• ensuring tissue specificity by targeted delivery.  
In order to attain these aims, more detailed objectives of the thesis were:  
1. An attempt to explain and understand the role of each lipid component in 
context with delivery efficiency. This goal was to be achieved by synthesis 
and following screening of a small lipidoid library based on oligoalkylamines 
with determining critical structure-activity relationships, side-by-side com-
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parison of the additional lipid components of the formulation, namely help-
er lipids and a PEG-lipid.  
2. Defining the critical requirements for effective endosomal escape and pro-
tein translation through analysis of the cellular steps involved in the trans-
fection process, i.e. cellular uptake in context with cell viability. 
3. Better understanding of such multicomponent system by investigation of 
nonlipidic factors influencing the particle formation and physicochemical 
characterization of resulting nanoparticles.  
4. Finally, in vivo testing as a proof of concept, both comparing different for-
mulations in terms of their efficiency using a reporter mRNA sequence as 
well as testing functional protein translation by using mRNA coding for a tox-
in in a mouse tumour model. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Solvents and chemicals 
All chemicals and reagents were purchased in quality reagent grade or higher from 
commercial sources (Sigma-Aldrich (St. Louis, USA), EvoBlocks (Budapest, Hungary)) 
and used as received. Two kinds of water were used: water for injection (Aqua ad 
iniectabilia®, B. Braun (Melsungen, Germany)) and bidestilled water (Aqua bidest., 
Kerndl (Weissenfeld, Germany)). Anhydrous solvents were purchased from Carl 
Roth (Karlsruhe, Germany). A set of screened oligoalkylamines consisted of: (2-2): 
Diethylenetriamine, (3-3): N-(3-aminopropyl)-1,3-propanediamine, (2-2-2): Triethyl-
enetetramine, (3-3-3): N,N’-Bis(3-aminopropyl)-1,3-propanediamine, (2-3-2): N,N’-
Bis(2-aminoethyl)-1,3-propanediamine.  
(2-3-2) dendrimers generations G1 and G2 were synthesized and supplied by SyMO-
Chem (Eindhoven, the Netherlands).  
2.1.3 Lipids 
Table 2.1 .  List  of  used l ipids ,  their abbreviat ions and suppliers .   
Abbreviation Full name Supplier 
DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine Avanti Polar Lipids  
(Alabastar, USA) 
DLPC 1,2-dilauroyl-sn-glycero-3-phosphocholine Avanti Polar Lipids  
(Alabastar, USA) 
DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine Avanti Polar Lipids  
(Alabastar, USA) 
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine Avanti Polar Lipids  
(Alabastar, USA) 
DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine Avanti Polar Lipids  
(Alabastar, USA) 
DePC 1,2-di-O-hexadecyl-sn-glycero-3-phosphocholine Avanti Polar Lipids  
(Alabastar, USA) 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine Avanti Polar Lipids  
(Alabastar, USA) 
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Cholesterol Cholesterol, plant derived Avanti Polar Lipids  
(Alabastar, USA) 
DMPE-PEG2k 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-methoxy(polyethylene 
glycol) (ammonium salt), 2000 Da 
Avanti Polar Lipids  
(Alabastar, USA) 
DMG-PEG2k/5k 1,2-Dimyristoyl-sn-glycerol-methoxy(polyethylene 
glycol), 2000/5000 Da 
NOF America Corporation 
(White Plains, USA) 
DPG-PEG2k/5k 1,2-Dipalmitoyl-sn-glycerol-methoxy(polyethylene 
glycol), 2000/5000 Da 
NOF America Corporation 
(White Plains, USA) 
DSG-PEG2k 1,2-Distearoyl-sn-glycerol-methoxy(polyethylene 
glycol), 2000 Da 
NOF America Corporation 
(White Plains, USA) 
DOPE-PEG2k 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-methoxy(polyethylene glycol) (ammonium salt), 
2000 Da 
Avanti Polar Lipids  
(Alabastar, USA) 
Cholesterol-
PEG2k 
Cholesterol-polyethylene glycol, 2000 Da NOF America Corporation 
(White Plains, USA) 
DSPE-PEG2k N-(Carbonyl-methoxy(polyethylene glycol))-1,2-
distearoyl-sn-glycero-3-phosphoethanolamine, 
sodium salt, 2000 Da 
NOF America Corporation 
(White Plains, USA) 
DSPE-PEG2k-FA DSPE-PEG-Folic acid, 2000 Da Nanocs (New York, USA)  
DOPS 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodi-
um salt) 
Avanti Polar Lipids  
(Alabastar, USA) 
 
2.1.4 Chemically modified mRNA 
Chemically modified mRNAs (cmRNAs) coding for firefly luciferase, Metridia lucifer-
ase, A-chain abrin, and human erythropoietin were supplied by Ethris (Planegg, 
Germany). Genes of interest were cloned into plasmid vector pVAXA120, linearized 
by restriction digestion with NotI, and further purified by chloroform/ethanol and 
sodium acetate precipitation. Resulting linear DNA template was used for in vitro 
transcription (IVT) from ribonucleotide mixture containing adenosine-triphosphate 
(ATP), guanosine-triphosphate (GTP), uridine-triphosphate (UTP) and cytosine-
triphosphate (CTP) as well as the chemically modified 5-methyl-CTP (25% of total 
CTP) and 2-thio-UTP (25% of total UTP) (Jena Bioscience GmbH, Jena, Germany). IVT 
was performed with RiboLock Rnase Inhibitor, Inorganic Pyrophosphatase, T7 RNA 
Polymerase, and DNAse I (Thermo Fisher Scientific (Waltham, USA)). The obtained 
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cmRNA was subsequently subjected to the post-capping process in the presence of 
GTP, S-Methyladenosine, Vaccinia Virus Capping Enzyme, and mRNA Cap 2’-o-
Methyltransferase (New England Biolabs (Ipswich, USA)). The final product was puri-
fied by ammonium acetate precipitation, and the resulting pellet was re-suspended 
in water for injection (WFI). cmRNA concentration and purity were determined with 
a NanoDrop 2000C spectrophotometer (Thermo Fisher Scientific (Waltham, USA)). 
2.1.5 Cell culture 
All cell culture consumables (flasks, plates) were purchased from Corning Incorpo-
rated (New York, USA). Growth media and additives (fetal bovine serum (FBS), peni-
cillin/streptomycin (P/S)) were purchased from Gibco Life Technologies (Darmstadt, 
Germany). All cell lines were purchased from DSMZ (Braunschweig, Germany) or 
isolated at Ethris (Planegg, Germany). List of tested cell lines, according culture me-
dia as well as the provider’s cell line number is presented in the table below:  
 
Table 2.2.  List  of  tested cell  l ines ,  their providers  and media.   
Cell line Description Provider Medium 
NIH 3T3 murine fibroblasts DSMZ – ACC 59 DMEM+  
10% FBS, 1% P/S 
HepG2 human liver carcinoma cells DSMZ – ACC 180 RPMI 1640  
10% FBS, 1% P/S 
AMSC adipose mesenchymal stem 
cells 
isolated from the fat tissue 
of a male rat, Ethris 
DMEM+  
10% FBS, 1% P/S 
A549 human alveolar type II like 
cells 
DSMZ – ACC 107 MEM+  
10% FBS, 1% P/S 
KB human cervix carcinoma 
(derivative of HELA) 
DSMZ – ACC 136 RPMI 1640 without 
folic acid  
10% FBS, 1% P/S 
KB  
for in vivo 
human cervix carcinoma 
(derivative of HELA) 
DSMZ – ACC 136 RPMI 1640 without 
folic acid  
10% FBS 
 
2 Materials and Methods 
18 
 
2.2 Methods 
2.2.1 Synthesis of lipidoids 
The lipidoids were synthesized in the reaction of selected oligoalkylamines with 
alkyl epoxide, as shown in Scheme 2.1. 100 mg of oligoalkylamine (corresponding to 
i.e. 0.623 mmol N,N’-Bis(2-aminoethyl)-1,3-propanediamine, (2-3-2)) was mixed 
with (N-1) equiv. of 1,2-epoxydodecane (corresponding to 575.07 mg, 3.12 mmol in 
the case of (2-3-2)), where N is defined as 2x number of primary amines plus num-
ber of secondary amines in one molecule of oligoalkylamine and stirred for 96 h at 
80°C in a glass vial, as performed by Love et al.[44] 
 
 
Scheme 2.1 .  Synthesis  of  oligoalkylamine -based l ipids .  
2.2.2 Complex formation and physicochemical characterization 
2.2.2.1 Lipoplex formation 
Lipid particles were formulated from a lipidoid (Ethris), two helper lipids: a phos-
pholipid and cholesterol (Avanti Polar Lipids) and a PEG-lipid (Avanti Polar Lipids or 
NOF America Corporation) at the molar ratios 8/5.29/4.41/0.88, if not stated differ-
ently. Proper volumes of lipid stock solutions in absolute ethanol of concentrations 
50, 20, 20 and 20 mg/mL, respectively, were combined and adjusted to a total vol-
ume of 200 µL. Lipoplex formation was performed by a rapid solvent exchange; lipid 
mixture in ethanol was injected into 800 µL of mRNA in citrate buffer (10 mM citric 
acid, 150 mM NaCl, pH 4.5, if not stated differently). Final mRNA concentration was 
200 µg/mL with N/P 17 or 8, if not stated differently. After 30 min of incubation at 
RT, lipoplexes were purified by overnight dialysis (in 7000 molecular weight cutoff 
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cassettes, Thermo Fisher Scientific (Waltham, USA)) against bidest. water. The con-
centration of mRNA in samples and encapsulation efficiency were determined by a 
modified RiboGreen assay (see below).  
When higher concentration of lipoplexes was required for in vivo experiments, it 
was obtained by using Eppendorf Concentrator plus device (Eppendorf (Hamburg, 
Germany)) with heating (45°C) and vacuum for rapid evaporation of excessive vol-
ume. If samples had to be frozen, they were adjusted with 20% sucrose to obtain 
final desired concentration of mRNA in 2% sucrose and stored at -20°C.  
2.2.2.2 RiboGreen Assay 
To determine the mRNA concentration of lipoplex fractions, a standard curve of 
unpurified sample (concentration known and equal to 200 µg/mL) in the range of 0-
4000 ng/mL for each composition was prepared. Samples were diluted 50 to 100-
fold to obtain the expected concentration within that range. 150 µL of each calibra-
tion point and diluted sample was treated with 140 µL 2% Triton X-100 and 10 µL 
heparin (40 mg/mL) and incubated for 15 min at 70°C. After cooling to RT, 100 µL of 
each sample was transferred in duplicates into a black 96-well plate, followed by 
addition of 100 µL of 100-fold diluted RiboGreen (Quant-iT™ RiboGreen® RNA Assay 
Kit, Invitrogen (Carlsbad, USA)) reagent (solution in dimethyl sulfoxide) in 1x TE 
buffer (10 mM Tris-HCl, 1 mMEDTA, pH 7.5 in diethylpyrocarbonate (DEPC)-treated 
water) into each well and light-protected incubation for 5 min at RT. The fluores-
cence intensity was measured on a multilabel reader (1420 Multilabel Counter, Per-
kin Elmer (Waltham, USA)) at excitation/emission wavelength of 485/535 nm, re-
spectively, with an untreated sample as control. The encapsulation efficiency was 
calculated from comparison of the signals of treated samples and untreated con-
trols. It was assumed that the signal in untreated samples comes from unentrapped 
mRNA, whereas in treated samples – from total mRNA.  
2.2.2.3 Size and zeta potential determination 
Hydrodynamic diameter of particles was measured by dynamic light scattering (DLS) 
using a Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK) with an auto-
matic attenuator and reported as intensity particle size distribution. Samples were 
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prepared by dilution of 10 µg complexed mRNA in 1 mL PBS buffer/WFI and meas-
ured at 25°C. Zeta-potential was calculated from electrophoretic mobility. 
2.2.2.4 Transmission electron microscopy (TEM) 
To make carbon-formvar copper grids 300 mesh (Ted Pella, (Redding, USA)) hydro-
philic, plasma cleaning was performed. 8 μL of sample was applied to a carbon-
formvar grid for 1 min and then the excess of sample was removed with a filter pa-
per. Negative staining of the sample was performed with 7 μL of a 1% uranyl ace-
tate solution in water. Remaining uranyl acetate solution was removed with a filter 
paper. Grids were imaged with JEM 1011 (JEOL (Tokyo, Japan)) at 80 kV. TEM pic-
tures were taken by Maximilian Utzinger, Ethris (Planegg, Germany) and Susanne 
Kempter, Department of Physics, LMU (Munich, Germany).  
2.2.2.5 Buffering capacity 
Prior to the potentiometric titration, 10 µmoles of lipidoids were dissolved in 1 mL 
ethanol and mixed with 2.5 mL 50 mM sodium chloride solution with the following 
pH adjustment to pH 2 with 0.5 M HCl. Experiments were performed on a potenti-
ometric titrator Titrando (Metrohm (Herisau, Switzerland)) with an automated dos-
ing. Measurements points were collected after each addition of defined volume of 
50 mM sodium hydroxide and following pH determination. As a blank, 3.5 mL of 
50 mM NaCl solution were titrated. The first detected pH value above 11 deter-
mined the end of titration. In order to calculate the volume of 50 mM NaOH re-
quired to reach certain, pH values between the real measurement points a linear 
regression between two nearest values was taken as an estimation. Buffering ca-
pacity was defined as a volume of 50 mM NaOH required to change pH by 0.1. 
2.2.2.6 Agarose gel electrophoresis 
The integrity of mRNA released from lipoplexes was determined by agarose gel 
electrophoresis. The samples were loaded on 1% (w/v) agarose (in TEA buffer 
(40 mM Tris, 20 mM acetic acid and 1 mM EDTA in distilled, deionised water; pH 
8.5) with a fluorescent dye PeqGREEN (0.005% v/v (i.e. 75 µL per 150 mL agarose 
gel), Peqlab (Erlangen, Germany)). The amount of mRNA varied between 500 and 
700 ng depending on the sample concentration. Samples in the volume of 5 µL were 
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treated with 3 µL heparin (40 mg/mL) and 2 µL Triton-X-100 (2%) and mixed with 
10 µL 2x RNA loading dye to a total volume of 20 µl. Next, samples were heated to 
70°C for 15 min in order to denature mRNA. Samples were cooled down on ice for 
2 min prior to loading on a gel. Electrophoresis was conducted at 150 V for 60 min 
and resulting gel imaging was performed with ChemiDoc XRS+ station (Bio-Rad 
(Hercules, USA)).  
2.2.3 In vitro methods 
2.2.3.1 Cell transfection 
Cells were cultured in appropriate medium (as listed in Table 2.3) at 37°C, 5% CO2. 
Cells were seeded at densities as showed in Table 2.3 in 100 µL media in a 96-well 
plate (collagen-coated in the case of HepG2) 24 h prior to transfection. The appro-
priate amount of complexed mRNA was added in 20 µL/well in triplicates after dilu-
tion series in PBS buffer starting from 500 ng/well if not stated differently. Plates 
were incubated for 24 h at 37°C, 5% CO2.  
Table 2.3.  Seeding conditions  of  tested cell  l ines .   
Cell line NIH 3T3 HepG2 AMSC A549 KB 
Medium 
DMEM+ 
10% FBS, 1% 
P/S 
RPMI 1640 
10% FBS, 1% 
P/S 
DMEM+ 
10% FBS, 1% 
P/S 
MEM+ 
10% FBS, 1% 
P/S 
RPMI 1640 
without folic 
acid 
10% FBS, 1% 
P/S 
Seeding cell 
density 
[cell/well] 
5000 20000 3000 20000 10000 
 
Transfection with folate receptor targeting was performed stepwise. First step as-
sured receptor saturation (with temperature inhibited uptake), where cells after 
10 min preincubation on ice were treated with 20 µL 250 mg/mL sodium folate and 
incubated on ice for 15 min. Second step was the particle uptake, where transfec-
tion was conducted as described above with following 30 min incubation at 37°C, 
5% CO2. Third step allowed reporter protein translation, where after media change 
cells were incubated for 24 h at 37°C, 5% CO2.  
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2.2.3.2 Firefly luciferase assay 
After 24 h of incubation, medium was removed. Cells were lysed in 100 µL of lysis 
buffer (25 mM Tris-HCl, 0.1 % TritonX-100, pH 7.8) and incubated on a plate shaker 
for 30 min at RT and 600 rpm. Next, 80 µL cell lysate from each well was transferred 
to a 96-well plate and the activity of reporter protein firefly luciferase was meas-
ured by bioluminescence intensity on a multilabel reader (1420 Multilabel Counter, 
Perkin Elmer (Waltham, USA)) after addition of a luciferin buffer (0.47 mM D-
luciferin, 0.27 mM Coenzyme A, 3.33 mM DTT, 0.53 mM ATP, 1.1 mM magnesium 
carbonate, 2.7 mM magnesium sulphate, 20 mM TRICINE, 0.1 mM EDTA). The lumi-
nometry at each well was measured for 1 s and expressed in relative light units 
(RLU).  
2.2.3.3 Cytotoxicity studies 
The effect of the lipoplexes on cell viability was determined by MTT Cell Prolifera-
tion Assay (TACS®, Trevigen (Gaithersburg, USA)) according to the manufacturer’s 
protocol. Briefly, 24 h post transfection medium in each well was exchanged and 
10 µL MTT reagent added. After 2.5 h incubation (37°C, 5% CO2) 100 µL detergent 
was added to each well and light-protected plates were incubated for 2 h at RT. 
Photometric measurement was performed at 570 nm on a multilabel reader (1420 
Multilabel Counter, Perkin Elmer (Waltham, USA)). Cell viability was calculated as a 
relative value (in %) compared to the control, untransfected cells (100%).  
2.2.3.4 Lipoplex uptake 
Confluent NIH 3T3 cells were seeded in 6-well plates at 300,000 cells/well. 24 h af-
ter seeding, cells were transfected with 930 ng mRNA-MetLuc complexed in lipo-
plexes C12-(2-2), C12-(3-3), C12-(2-2-2), C12-(3-3-3) or C12-(2-3-2). After 0.5, 1, 2, 
and 4 h time points cells were washed with PBS and lysed with a lysis buffer (LBP, 
Macherey-Nagel (Düren, Germany)). The total RNA was isolated according to the 
manufacter’s protocol (NucleoSpin RNA plus kit, Macherey-Nagel (Düren, Germa-
ny)) and eluted in 40 µL RNase-free water. The resulting concentration and purity 
were determined by spectrophotometry at 260 and 280 nm (NanoDrop 2000c, 
Thermo Fisher Scientific (Waltham, USA)). 1 µg RNA of each sample was reversely 
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transcribed into cDNA with anchored-oligo(dT)18 primer (Transcriptor First Strand 
cDNA Synthesis Kit, Roche (Basel, Switzerland)). mRNA-MetLuc amounts (for each 
construct, after each time point) were quantified by quantitative PCR (qPCR, Uni-
versal Probe Library, UPL #14, Roche (Basel, Switzerland)) in 100-fold diluted cDNA 
based on a standard curve of pure mRNA-MetLuc transcribed into cDNA (102-107-
fold dilutions) on a LightCycler 96 System, Roche (Basel, Switzerland). qPCR mixture 
per sample contained: 3.5 µL water, 0.5 µL 20 µM forward DNA primer, 0.5 µL 
20 µM reverse DNA primer, 0.5 µL UPL and 10 µL Master Mix (provided in a kit).  
DNA primers were designed with an online tool available at 
https://lifescience.roche.com/. Primer sequences were synthesized by Eurofins Ge-
nomics (Ebersberg, Germany).  
 
DNA primer sequences:  
Forward: AACCTGGAAACCGACCTGT 
Reverse: ATCGGCCTTGATCATCACTT 
2.2.3.5 Bright microscopy 
Bright imaging of transfected cells was performed with JuLI – smart fluorescent cell 
analyser (Ruskinn Technology (Bridgend, UK) 24 h after transfection.  
2.2.3.6 mRNA release assay 
Preparation of anionic liposomes (AL): Stocks of 1,2-dioleoyl-sn-glycero-3-phospho-
L-serine (sodium salt) (DOPS), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) in chloroform (20 mg/mL) 
were mixed in proper volumes to obtain molar ratios 1:1:2, respectively. Next, sol-
vent was evaporated from the mixture under a stream of nitrogen and the resulting 
lipid film was subsequently resuspended by vortexing and sonication in PBS buffer 
pH 6 to obtain final DOPS concentration of 5 mg/mL.  
Sample treatment: tested lipoplexes were mixed with murine plasma at equal vol-
umes and incubated at 37°C for 20 min. Next, AL were added to the sample in a 
desired ratio of DOPS to C12-(2-3-2) and further incubated at 37°C for 15 min. As a 
plasma control served the sample with PBS buffer added instead of AL.  
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mRNA release determination: samples were diluted to obtain concentration in the 
range of RiboGreen linear response (0-4,000 ng/mL). The following procedure of 
mRNA quantification of total and encapsulated mRNA is described in Chapter 
2.2.2.2 “RiboGreen Assay”. mRNA release was defined as percentage of mRNA 
amount detected in untreated sample in relation to total mRNA quantified in sam-
ples treated with Triton X-100 and heparin (100%).  
Relative mRNA release: the value of relative mRNA release was determined as a 
ratio of mRNA release in samples treated with murine plasma and AL (in %, deter-
mined as described in “mRNA release determination”) to mRNA release in plasma 
control samples (PBS buffer instead of AL added to the sample), also expressed in %.  
The procedure of mRNA release assay is schematically presented in Figure 2.1.  
 
Figure 2.1 .  Scheme of  sample treatment in mRNA release assay.   
 
Relative mRNA release was calculated according to the equation below:  
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑚𝑅𝑁𝐴 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 =
𝑚𝑅𝑁𝐴 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑖𝑛 𝐴𝐿 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒
𝑚𝑅𝑁𝐴 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑖𝑛 𝑝𝑙𝑎𝑠𝑚𝑎 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
=
𝑅𝑖𝑏𝑜𝐺𝑟𝑒𝑒𝑛 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑐)
𝑅𝑖𝑏𝑜𝐺𝑟𝑒𝑒𝑛 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑑)
∗ 100%
𝑅𝑖𝑏𝑜𝐺𝑟𝑒𝑒𝑛 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑎)
𝑅𝑖𝑏𝑜𝐺𝑟𝑒𝑒𝑛 𝑠𝑖𝑔𝑛𝑎𝑙 (𝑏)
∗ 100%
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2.2.4 Animal studies 
All experiments were performed according to German animal welfare law and were 
authorized by the local animal welfare authorities (Regierung von Oberbayern). Six 
to eight weeks old female Balb/c mice were obtained from Charles River Laborato-
ries (Sulzfeld, Germany) and kept under specific pathogen-free conditions undergo-
ing a 12 h/12 h light/dark cycle with free access to food and water. Animals were 
conceded an adaption time of at least 7 days prior to begin of experiments. 
2.2.4.1 Tail vein injection and luciferase activity 
Tail vein injection experiments as well as luminescence imaging and quantification 
were performed by Dr. Tamara Pasewald, Ethris (Planegg, Germany).  
The lipidic formulations in a volume of 140-150 μL in PBS each, containing 18-20 μg 
of mRNA-FLuc were injected into the tail vein (needles for injection: Microfine+ 
1 mL, 0.33 mm (29G) x 12.7 mm (BD (Franklin Lakes, USA))) of a mouse fixed in a 
gadget. Luciferase activity was determined 6 h post administration. Mice were anes-
thetized through intraperitoneal injection of Medetomidin (0.5 mg/kg), Midazolam 
(5 mg/kg) and Fentanyl (0.05 mg/kg) followed by application of the substrate D-
luciferin. Bioluminescence was measured 10 min later using a Xenogen IVIS In Vivo 
Imaging System 100 (Caliper Life Sciences (Waltham, USA) with an exposure time of 
1 min. Quantification of a signal was performed with a software Living Image (Per-
kin Elmer (Waltham, USA)).  
2.2.4.2 Tumour culture and treatment 
mRNA coding for the toxin abrin was produced and tested by Kristin Hirschberger, 
Ethris (Planegg, Germany). In vivo experiment was performed by Eva Kessel, De-
partment of Pharmacy, LMU (Munich, Germany).  
KB cells for in vivo experiment were cultivated in RPMI 1640 media without folic 
acid containing 10% FBS and no antibiotics at 37°C, 5% CO2 in a humidified atmos-
phere for two weeks before harvesting. After harvesting cells were resuspended in 
cold PBS to a concentration of 5x106 cells/150 µL. Until the subcutaneous injection 
into mice (strain RjOrl:NMRI-Foxn1nu /Foxn1nu; 6 weeks old females) on the same 
day, cells were stored on ice. As soon as tumours reached a sufficient size (around 
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250 mm3), lipoplexes were applied via intratumoral injection to anesthetized mice 
(inhalational anesthesia performed with isoflurane) three times a week. Injections 
were performed on the same day for all animals with a perceptible tumour with the 
injection volume of 50 µL containing 10 µg of mRNA and total injection number: six 
for toxin mRNA encapsulated in targeted lipoplexes, control mRNA in nontargeted 
lipoplexes, and 2% sucrose control or four in the case of control mRNA in targeted 
lipoplexes. Animals were examined daily with respect to inspections of the skin/fur, 
eyes, mucous membranes, respiratory and circulatory systems, somatomotoric ac-
tivity, behaviour patterns and body weight. Tumour size were measured daily with a 
caliper using formula “a x b²/2” with “a” indicating the length of the tumour and “b” 
the width. Tumour size and weight were also determined ex vivo. Blood samples 
were collected from the heart using EDTA tubes and analyzed by a Sysmex KX-21N 
system at Ethris GmbH to determine the following parameters: white blood cells, 
red blood cells, haemoglobin, haematocrit and platelets. Remaining blood samples 
were centrifuged at 2000 x g for 5 min at 4°C and the EDTA-containing supernatant 
were stored at -80°C until used for analysis. Cytokines (IL-10, IL-1ß, IL-2, IP-10, IL-6, 
IFN-α, IFN-γ, IL-12p70, TNF-α and MCP-1) were measured according to the Ethris’ 
protocols using ProcartaPlex™ Multiplex Immunoassay custom kits (eBioscience 
(San Diego, USA)) in combination with the Magpix instrument (Luminex Corporation 
(Austin, USA)). Mice were euthanized by cervical dislocation.  
IVIS luminescence imaging was performed 24 h after intratumoral treatment. 
100 µL of luciferin (60 mg luciferin/mL PBS) was administered intraperitoneally 
15 min prior to imaging process.  
2.2.5 Statistical analysis 
Data are presented as means ± SEM. The significant differences between the groups 
were analyzed by one-way ANOVA, and a P value of <0.05 was considered signifi-
cant. 
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3 Results 
The subject of this thesis was the development and characterization of a lipid-based 
carrier for mRNA delivery in vivo that would fulfil criteria of high efficiency and sta-
bility without toxic side effects. Specifically, the ultimate goal was to target the liver 
via systemic administration. Since many metabolic processes are related to this or-
gan, transcript therapy could enable treatments for a wide variety of genetic dis-
eases. Similar to most nucleic acid based macromolecular drugs, extracellular stabi-
lization and efficient intracellular transport represent the bottleneck in the devel-
opment of an mRNA-therapeutic product. Since mRNA as a single stranded mole-
cule has different physical properties than other nucleic acids, there is a high de-
mand for the development of lipid-based vehicles tailored to the characteristics of 
mRNA. 
Based on a literature search on nucleic acid delivery, a model system using mRNA 
coding for a reporter protein and four lipidic components (a lipidoid, two helper 
lipids and a PEG-lipid) was chosen. From this starting point, side-by-side compari-
sons of each presumably influencing factor, mostly in terms of transfection efficien-
cy, were made in order to optimize formulations for mRNA delivery. The results are 
presented and described in the following chapters. Each experiment was performed 
using the same composition, nitrogen to phosphate (N/P) ratio, formulation condi-
tions etc., unless stated differently. (A list of all formulations has been added to the 
appendix)  
3.1 Lipidoids 
Lipidoids were chosen for the first component screening. A lipidoid enables encap-
sulation of a polyanionic biomolecule via electrostatic interactions and facilitates 
the cellular uptake as well as endosomal escape of a complex. The selected modifi-
cation method, variations of a backbone and alkyl chain length are presented in the 
next chapter.  
 
3 Results 
28 
 
3.1.1 Oligoalkylamine-based backbone 
This chapter has been partly adapted from: 
Jarzębińska, A., Pasewald, T., Lambrecht, J., Mykhaylyk, O., Kümmerling, L., Beck, P., 
Hasenpusch, G., Rudolph, C., Plank, C. and Dohmen, C., 2016. A Single Methylene 
Group in Oligoalkylamine‐Based Cationic Polymers and Lipids Promotes Enhanced 
mRNA Delivery. Angewandte Chemie International Edition, 55(33), pp.9591-9595.  
As small oligoalkylamine structures are known for effective carriers of various nucle-
ic acids, five lipidoids based on such scaffolds were synthesized as shown in Scheme 
3.1a. A small set of tri- (2-2, 3-3) and tetramines bearing ethylene (2-2-2) and/or 
propylene spacers (2-3-2, 3-3-3) were modified with C12 alkyl chains by applying 
the method reported by Love et al.[44] Purification of the lipids was circumvented by 
performing a one-pot reaction with a ring-opening of CH3(CH2)9-epoxide (4 or 5 
equivalents, no excess) by oligoalkylamines (reaction on Scheme 3.1b; resulting li-
pids are shown in Scheme 3.1c).  
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Scheme 3.1.  a)  Structures of  oligoalkylamines .  b)  Synthesis  of  oligoalkylamine -based l ipids .c)  Struc-
tures  of  C12-decorated ol igoalkylamines .   
 
Resulting C12-oligoalkylamine lipidoids were subsequently screened for their buff-
ering capacity, characterized in terms of physicochemical properties and transfec-
tion efficiency in lipid nanoparticles as described in the following chapters.  
Buffering capacity as a predictor of endosomal escape capability 
The cellular uptake pathway of lipoplexes usually comprises endocytosis.[62] The 
transfection efficacy is dependent on complex release from the endosome into the 
cytosol to avoid lysosomal degradation. It is hypothesized that a key parameter 
which determines transfection efficiency of any nucleic acid delivery agent is an acid 
c) 
a) b) 
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dissociation constant, i.e. a pKa value pKa <7. Optimal values are in a pH range of 6.2 
to 6.5, which enhance endosomal escape of the carrier complex into the cytoplasm 
through membrane disruption by positively charged nanoparticle surface.[21] This 
step could be expected to be critical in the process of mRNA delivery as well and 
therefore, the buffering capacity for each structure was determined by potentiom-
etric titration to predict their potency in mRNA delivery (Figure 3.1).  
 
Figure 3.1 .  Plots  of  buffering capacit ies  of  C12 -lipids  with oligoalkylamine backbones.  The  area in 
between the dotted l ines indicates  the ideal  buffering range for nucleic acid carriers ,  enhancing 
endosomal escape.  Buffer ing capacity β  was defined as  volume of  50  mM NaOH added to  the solution 
containing 10 mmoles  l ipid resulting in a pH change of  0.1.  
 
Whereas the lipid-derivatized triamines (C12-(2-2) and C12-(3-3)) did not possess 
any increased buffering capability in the tested range (5.1 – 8.0), the tetramines 
exhibited clear maxima in different pH ranges. However, for C12-(3-3-3) and -(2-2-
2), these were above and/or below pH 6.2 and 6.5. Only the C12-(2-3-2) displayed a 
peak buffering capacity in the desired range and, hence, was a promising candidate 
for further evaluation. 
Physicochemical properties of lipoplexes 
Therapeutic nanoparticles have to fulfil some physicochemical requirements which 
play a critical role in drug stability, uptake, and efficiency in vivo. Therefore, this is 
the focus of the following chapter. In order to obtain nanoparticles, lipidoids were 
complexed with chemically modified mRNA together with two helper lipids and 
a PEG-lipid. Resulting lipoplexes were characterized in terms of their physicochemi-
cal properties, namely size, zeta potential, and encapsulation efficiency.  
The summarized data is presented in Table 3.1 and Figure 3.2.  
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Table 3.1 .  Hydrodynamic diameter,  zeta potential  and encapsulation eff iciency of  l ipoplexes .  
 Lipid C12- 
Oligoalkylamine (2-2) (3-3) (2-2-2) (3-3-3) (2-3-2) 
Hydrodynamic 
diameter [nm] 
61.0±0.9 56.1±0.7 68.8±0.9 54.0±0.3 59.7±0.7 
Polydispersity (PDI) 0.227±0.012 0.189±0.005 0.143±0.004 0.154±0.003 0.162±0.002 
Zeta potential [mV] 14.6±0.8 0.6±0.5 -1.5±0.1 -0.4±1.0 -0.9±0.4 
Encapsulation effi-
ciency [%] 
96 100 90 98 97 
 
Lipid-based nanoparticles were found to comprise uniform particles with hydrody-
namic diameter between 54 and 61 nm and a neutral or slightly positive zeta poten-
tial. The process of mRNA complexation determined by RiboGreen was found to be 
efficient (>90% encapsultion efficiency, Table 3.1). However, some discrepancies 
could be observed: lipids with ethylene spacers led to lower encapsulation efficien-
cy values compared to their counterparts with propylene spacers (96% for C12-(2-2) 
and 100% for C12-(3-3); 90% for C12-(2-2-2) and 98% for C12-(3-3-3)). The lipoplex-
es with the alternating structure lipid led to relatively high encapsulation efficiency 
as well (97%).  
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Figure 3.2 .  Transmission electron microscopic (TEM) images of  C12 -(2-3-2) l ipoplexes .  
Transmission electron microscopy images revealed the spherical shape of the re-
sulting lipoplexes. Moreover, the observation from an agarose gel (Figure 3.3) 
proved that the encapsulated mRNA molecules remained intact. 
 
Figure 3.3.  Agarose gel  of  C12-(2-2) ,  -(3-3),  -(2-2-2),  -(3-3-3) and –(2-3-2) l ipoplexes ,  (numbered 1-
5,  respect ively) ,  treated with heparin and Triton X -100. L=mRNA ladder.   
 
All particles formed from tested lipidoids exhibited comparable physicochemical 
properties meeting the requirements of nucleic acid complexes.  
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Cellular uptake 
Since sufficient particle uptake is a prerequisite for high transfection efficiency, the 
efficacy of this process was determined for each tested lipidoid. Therefore, the 
amounts of reporter mRNA in NIH 3T3 cells treated with lipoplexes (in a dose of 
~3 pg mRNA per cell) were quantified via qPCR. Briefly, cells were incubated with 
lipoplexes varying in the type of lipidoid and after 0.5, 1, 2, or 4 h the amount of the 
reporter mRNA was evaluated based on a standard curve of pure mRNA of the same 
sequence (Figure 3.4).  
 
Figure 3.4.  Levels  of  l ipoplex uptake in NIH 3T3 cells  after 0.5 ,  1,  2 ,  and 4 h of  incubation expressed 
as  detected Metridia luciferase mRNA am ount per cell .  Complexes were applied at doses  of 3.1  pg 
mRNA/cell .  (NC = negative control ,  untreated cells)  
Already 0.5 h after transfection, high levels of reporter mRNA in the cells were ob-
served for C12-(3-3-3) and C12-(2-3-2). In the case of C12-(2-2-2), relatively steep 
increase with time could be noted, whereas for C12-(3-3-3) the values stayed at 
almost the same level, independently of the time point. In general, the lipoplex up-
take in C12-(2-3-2), C12-(3-3-3), and C12-(2-2-2)-treated cells was in the comparable 
range. It was noticeably lower for C12-(2-2) and hardly any uptake could be ob-
served for C12-(3-3).  
Cytotoxicity 
One possible reason for varying protein levels could be differences in toxic effects 
caused by transfection with lipoplexes. To exclude this factor a cell viability assay 
was conducted in parallel with transfection experiments. Briefly, 24 h after transfec-
tion with lipoplexes from the oligoalkylamine lipid library, an MTT assay was per-
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formed to evaluate metabolic activity of the cells, which correlates with their viabil-
ity. The untreated cells were used as a reference (100% viable cells). Results are 
shown in Figure 3.5.  
 
Figure 3.5.  Inf luence of  l ipoplexes on cell  viabil ity of  NIH 3T3 cells  24 h after transfection was eval-
uated using an MTT assay.  
 
The lipidoid C12-(2-2-2) was the least toxic structure from all tested ones, whereas 
triamine-based lipids as well as C12-(3-3-3) were less well-tolerated. However, at 
doses of complexed mRNA lower than 62 ng/well, 100% cells were viable after 
treatment with C12-(2-3-2) (all values referred to the negative control, untransfect-
ed cells). 
Transfection efficiency 
The most important characteristic of any potential drug is its functionality. In the 
case of mRNA-based therapeutic it is determined by the resulting protein level. 
Therefore, the set of oligoalkylamine-based lipidoids was screened in vitro on mu-
rine fibroblasts (NIH 3T3 cells) for their ability to transfect cells using chemically 
modified mRNA coding for firefly luciferase (mRNA-FLuc) as a reporter (Figure 3.6a) 
complexed additionally with of two helper lipids and a PEG-lipid. Since the lipoplex-
es were investigated with the aim of protein production in the liver after systemic 
administration, they were additionally tested on target tissue-derived, human liver 
carcinoma cells (HepG2, Figure 3.6b). Moreover, to learn more about structure-
activity relationship, two other cell types were transfected: lung-derived human 
alveolar type II like cells A549 and rat adipose tissue-derived stem cells AMSC (Fig-
ure 3.6c-d).  
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Figure 3.6.  Transfection eff ic iency of  l ipoplexes carrying mRN A-FLuc on a) murine f ibroblasts  (NIH 
3T3) ,  b) target tissue-derived human l iver carcinoma cells  (HepG2) ,  c)  human alveolar type II  l ike  
cells  (A549) ,  and d)  adipose mesenchymal stem cells  (AMSC)  .  The protein level  was deter mined 24 h  
post transfection by measuring bioluminescence expressed in counts  per second (cps) .  
 
In all four tested cell lines triamine-based lipidoids exhibited only low levels of re-
porter enzyme activity. In contrast, the lipidoids C12-(2-3-2) and C12-(2-2-2) led to 
decent protein levels in NIH 3T3, HepG2 and A549. Interestingly, the best perform-
ing lipidoid proved to be C12-(2-3-2) with alternating oligoalkylamine structure, 
reaching nearly 7-fold increase compared to second best C12-(2-2-2) (NIH 3T3, 
31 ng/well) and demonstrated high transfection efficiency even at low doses of 
mRNA. Importantly, the trend of superior efficiency of C12-(2-3-2) lipoplexes was 
independent of cell type, suggesting the existence of a more general structural rule. 
In vivo proof of concept 
With the goal of developing a carrier system suitable for intravenous application 
and enabling efficient protein translation in vivo, the potency of lipoplexes consist-
ing of tetramine-based lipids to deliver mRNA was investigated in female Balb/c 
mice. Triamine-based lipids were excluded from the experiment due to their lack of 
functionality in vitro. Animals were treated with a dose of 1 mg/kg via tail vein injec-
a) 
d) c) 
b) 
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tion. Bioluminescence images of the whole bodies, excised livers as well as quantifi-
cation of bioluminescence intensity 6 h after treatment are shown in Figure 3.7.  
 
 
Figure 3.7.  a)  Exemplary bioluminescence images of mice treated intravenously  with 18 µg mRNA-
FLuc complexed with C12-(2-3-2) ,  C12-(2-2-2),  and C12 -(3-3-3) .  b) Exemplary bioluminescence imag-
es  of  excised l ivers .  c)  Quanti f ication of  bioluminescence intensity in treated mice  (o bserved in (a)) .  
n=3. **p<0.01, ***p<0.001, and ****p<0.0001.  
 
Bioluminescence in animals treated with lipidoids C12-(2-2-2) and C12-(3-3-3) was 
at the background level, whereas a strong signal in the liver of C12-(2-3-2)-treated 
mice was observed (Figure 3.7a-c). Results from cell culture experiments which indi-
cated that the alternating structure is beneficial over the other oligoalkylamines 
was therefore confirmed also in an in vivo setting. 
In conclusion, by screening a set of oligoalkylamines for efficient delivery of mRNA 
in nanoparticles, it was found that a tetramine with alternating ethyl–propyl–ethyl 
spacers modified with C12 alkyl chains exhibited a high ability to mediate robust 
levels of protein translation in vitro as well as in vivo.  
a) 
c) b) 
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3.1.2 Oligoalkylamine-based dendrimers 
After finding that the motif based on (2-3-2) oligoalkylamine is successful in mRNA 
delivery in lipoplexes, the aim was to test if it may be modified to further improve 
mRNA delivery. Since the alternating structure proved to be critical for efficient 
translation of a nucleic acid, more complex, branched scaffolds based on it were 
investigated. For this purpose, (2-3-2)-dendrimers were chosen, as shown in 
Scheme 2. Lipid derivatives were synthesized from such scaffolds using the same 
method as described in Chapter 3.1.1. Two generations of (2-3-2)-dendrimers, G1 
and G2 were modified with alkyl epoxides of C8, C12, and C16 chain lengths (result-
ing scaffolds are summarized in Table 3.2) and subsequently tested in vitro as well 
as in vivo.  
 
Scheme 3.2.  Structures of  generations a) G1 and b) G2 of  (2 -3-2) dendrimers and c) synthesis  of 
dendrimer scaffolds  modif ied with alkyl  epoxides of  various carbon chain lengths on the example of 
G1 modif ied with C12-epoxide.   
 
Table 3.2.  A summary of  generated (2-3-2) dendrimers modif ied with alkyl  epoxides of  C8,  C12, and 
C16 chain lengths .   
Dendrimers Dendrimer generation 
Alkyl epoxide length G1 G2 
C8 C8-G1 C8-G2 
C12 C12-G1 C12-G2 
C16 C16-G1 C16-G2 
 
c) 
b) a) 
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All modified dendrimers were tested for their transfection efficiency in vitro in for-
mulations containing helper lipids and a PEG-lipid at N/P 10, with dendrimers serv-
ing as lipidoids (see Figure 3.8, C12-(2-3-2) (C12-G0) added as a reference).  
 
Figure 3.8.  Transfection eff iciency in murine f ibroblasts  (NIH 3T3) of  a)  G1 and b) G2 dendrimers  
modif ied with alkyl  epoxides of  various carbon chain leng ths .  c)  Bioluminescence of in vitro best 
performers ,  C16-G1 and C12-G2. in comparison with previously tested C12-(2-3-2),  C12-G0. Mice were 
treated intravenously with 20  µg mRNA-FLuc complexed with  corresponding l ipidoid ,  helper l ipids  
and a PEG-lipid .   
 
The two most promising carriers were identified in vitro: one from G1 and one from 
G2 group. Interestingly, one was modified with C16 alkyl chain and the other with 
C12 (C16-G1 and C12-G2, respectively). Therefore, these two formulations were 
tested in vivo as well, leading to detectable luminescence values. Both constructs 
were almost at the same level: C12-G2 was not even 2-fold more efficient than C16-
G1. However, in both cases bioluminescence was 100-fold lower than in the case of 
C12-(2-3-2) lipoplexes (corresponding formulation was added to Figure 3.8c as a 
reference, “C12-G0”). Worth noting, encapsulation efficiency yielded only 23% and 
49% in C16-G1 and C12-G2, respectively. 
a) 
c) 
b) 
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In summary, the extended alternating motif of oligoalkylamine in the form of den-
drimers was also able to deliver successfully mRNA into cells, both in vitro as well as 
in vivo. Nonetheless, the resulting mRNA translation did not reach the levels ob-
tained with the original structure of (2-3-2). 
3.1.3 Alkyl chain length of lipidoids 
Initial modifications of oligoalkylamines with alkyl chains were performed with 
CH3(CH2)9-epoxides, resulting in C12-lipids. In the next step the influence of alkyl 
chain length on the properties of a lipidic carrier was explored.  
Therefore, a screening of (2-3-2) oligoalkylamine-based lipids modified with C5-C16 
alkyl chains was conducted in vitro in terms of their transfection efficiencies (Figure 
3.9). Lipoplexes were formed in the same composition with mRNA-FLuc as a report-
er, varying only in the lipidoid.  
 
Figure 3.9.  Transfection eff ic iency of  l ipoplexes consisting of  (2 -3-2) l ipids  with dif ferent alkyl  chain  
lengths on murine f ibroblasts  (NIH 3T3) .  FLuc was used as  a reporter mRNA and t he protein level 
was determined 24 h post transfection by measuring bioluminescenc e expressed in counts  per second 
(cps) .   
 
For all tested lipidoids a dose-dependent increase in reporter level could be ob-
served, except the shortest alkyl chains C5 and C6-(2-3-2), which showed no trans-
fection at all. The drop in efficiency at the highest dose, 500 ng/well, was presuma-
bly due to toxicity of the particles. In the non-toxic dose range, C12 and C14 led to 
the best results. The efficiency seemed to decrease with either lower alkyl lengths 
(C10 and C8) as well as higher alkyl length (C16).  
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Based on in vitro results, C5 and C6 lipidoids were excluded from the in vivo study. 
The other five were tested in mice treated with a dose of 1 mg/kg via tail vein injec-
tion, as shown in Figure 3.10.  
 
Figure 3.10.  Quantif icat ion of  biolumine scence intensity in mice treated with l i poplexes consisting 
of  C8-,  C10- ,  C12- ,  C14- ,  and C16-(2-3-2).  
 
The results showed an alkyl chain length dependency with a maximal efficiency for 
C10-(2-3-2) and a decrease with both increasing and decreasing lengths. However, 
there was no significant difference between this alkyl chain and C12. Thus, both 
C10- and C12-(2-3-2) could be considered as the most promising lipidoids for mRNA 
delivery. 
3.2 Helper lipids 
The standard multicomponent lipoplex formulation described in this thesis con-
tained two helper lipids: cholesterol and a phospholipid. Whereas the neutral help-
er lipid, cholesterol contributes to rigidity and stability of lipid nanoparticles,[63] the 
role of a phospholipid in lipoplexes covers additionally electrostatic interactions in 
mRNA-lipid complexes.[50] In this chapter, the importance of the latter was tested as 
well as the influence of variations in the composition.  
3.2.1 Phospholipid type 
Since cholesterol seems to be a crucial component of lipid complexes, only the 
phospholipid type was tested in following experiments. As a starting point, 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was used in the formulation. At 
3 Results 
41 
 
first, the critical role of a phospholipid in general, a neutral lipid comprising two 
charges, was investigated by its replacement with cholesterol (Figure 3.11).  
 
 
Figure 3.11 .  a)  Structures of  three compared helper l ipids:  DSPC (R=C18:0) ,  cholesterol  and DOPE.  
b) Comparison of  transfection eff iciency  in murine f ibroblasts  (NIH 3T3) and c) in mice of  these help-
er l ipids  incorporated in l ipoplexes with FLuc.  d) Microscopic picture s  of  cells  (NIH 3T3) 24  h after 
transfection with l ipoplexes comprising helper l ipids  DOPE or DSPC.  
 
How important the presence of a phospholipid is, was clearly observed when DOPE 
was completely replaced by cholesterol. As shown in Figure 3.11b-c, barely any 
transfection occurred, both in vitro as well as in vivo for a formulation comprising 
only cholesterol. On the other hand, when DOPE was exchanged to another type of 
phospholipid, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), the transfection 
peak appeared again, although shifted to higher mRNA doses in vitro. Such a result 
d) 
b) c) 
a) 
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could indicate possibly a better tolerability of phosphocholines in comparison with 
phosphoethanolamines. This hypothesis was investigated by analyzing microscopic 
pictures of the treated cells (Figure 3.11d). DOPE formulations led to toxic effect 
down to the dose of 31 ng mRNA/well as indicated by the changed appearance of 
cells (round and shrunken), whereas DSPC formulations were well tolerated at dos-
es as high as 250 ng/well. The bioluminescence in mice (Figure 3.11c) after injection 
of lipoplexes comprising DOPE, DSPC, or cholesterol showed the same dependency 
as observed in vitro. A formulation without a phospholipid did not result in efficient 
mRNA translation. In addition, no significant difference between DOPE and DSPC 
could be noted in vivo.  
In conclusion, it was found that the presence of a phospholipid in lipoplexes is criti-
cal for their functionality. Moreover, the phospholipid type showed to have an im-
pact on both transfection efficiency and toxicity of a complex. 
3.2.2 Phospholipid alkyl chain length and saturation 
Due to better tolerability of phosphocholines (PCs) in vitro, this type of phospholipid 
became a subject of further studies. A series of different PCs varying between each 
other in alkyl chain length or its saturation were further tested both in vitro as well 
as in vivo. Three PCs with saturated alkyl chains: 16:0 (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, DPPC), 14:0 (1,2-dimyristoyl-sn-glycero-3-phosphocholine, DMPC) 
and 12:0 (1,2-dilauroyl-sn-glycero-3-phosphocholine, DLPC) were chosen as well as 
one with unsaturated alkyl chain, corresponding to its counterpart among phos-
phoethanolamines (DOPE), 18:1 (1,2-dioleoyl-sn-glycero-3-phosphocholine, DOPC), 
and diether 16:0 (1,2-di-O-hexadecyl-sn-glycero-3-phosphocholine, DePC). DSPC 
(18:0) was excluded from further experiments as it was found to form unstable par-
ticles (precipitate occurred after some time). The comparisons of lipoplex size, zeta 
potential, the efficiency in vitro and in vivo are shown in Figure 3.12.  
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Figure 3.12 .  Comparison of  a) s ize ,  zeta potential  and transfection eff iciency b) in murine f ibro-
blasts  (NIH 3T3) or c)  mice of  dif ferent phosphocholine -based helper l ipids  incorporated in l ipoplex-
es  with FLuc.  
 
Even though no major differences in size between particles could be observed, their 
zeta potential decreased with shorter alkyl chain lengths (from 42 down to 29 mV, 
Figure 3.12a). The lowest zeta potential was noted for diether chains, whereas the 
18:1 PC showed values comparable to 16:0 PC. The encapsulation efficiency of 
DOPC (18:1)-comprising lipoplexes was lower than of all others tested (87% com-
pared to 95-98%, data not shown), which was reflected by the lowest transfection 
efficiency (Figure 3.12b). Despite similar transfection efficiency of DLPC (12:0) com-
pared with the other formulations at high 500 ng/well, a sudden drop in efficiency 
was observed at lower doses. Whereas DMPC (14:0) and DePC (diether 16:0) 
showed similar transfection levels, DPPC (16:0) led to the highest recorded amounts 
of translated protein. In summary, it could be concluded from the in vitro experi-
ment that: i) the efficiency decreased with shorter alkyl chain length of a PC; ii) alkyl 
chain was beneficial over its diether counterpart; iii) saturated alkyl chains were 
more efficient than unsaturated ones. 
Interestingly, in vivo bioluminescence (Figure 3.12c) measurements showed the 
opposite trend with shorter saturated alkyl chains (16:0<14:0<12:0) leading to high-
c) 
b) a) 
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er efficiency as compared with in vitro results. Moreover, no significant difference 
could be observed between 16:0 alkyl and diether 16:0 chains. It also seemed that 
the unsaturated alkyl chain PC (18:1, DOPC) was more active in mRNA delivery than 
some saturated alkyl chain PCs. In conclusion, a tendency towards DLPC (12:0) and 
DOPC (18:1) as the most efficient in vivo was observed. 
3.2.3 Variations in the lipid composition 
Not only variations in components themselves, but also in ratios between them can 
have an impact on lipoplex formation, stability, charge transfer, and, hence, trans-
fection efficiency. As every single lipid plays a different role in mRNA delivery, it was 
important to determine how variation of the amounts of a single helper lipid (PEG-
lipids are described in Chapter 3.3) would influence the ability to deliver mRNA into 
cells. 
At first, the question about the effect of removing two or a single helper lipid was 
addressed. In this experiment (Table 3.3, 1st set), the amounts of a lipidoid 
C12-(2-3-2) and a PEG-lipid (DMG-PEG2k) were kept constant. One formulation con-
tained no helper lipids at all; three formulations contained no phospholipid (DPPC), 
whereas cholesterol amount was either lower, equal, or higher than in the standard 
formulation. Three formulations contained no cholesterol, whereas DPPC amount 
was either lower, equal, or higher than in the standard formulation. The second set 
of experiments (Table 3.3, 2nd set) was performed to test the influence of varying 
amounts of one of the helper lipids when the second helper lipid is present but in 
only small, constant quantity (amounts of cholesterol higher, equal, or lower than 
standard, while DPPC amount constantly low and the opposite). The third set of 
experiments (Table 3.3, 3rd set) was designed in order to verify whether reduced 
PEG-shielding would alter the influence of a single helper lipid. Here, the second 
helper lipid was also kept at a constant, low ratio. The conditions of all three sets of 
experiments are summarized in Table 3.3; differences in relation to the standard 
amounts were marked red.  
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Table 3.3.  Summary of  molar ratios  of  the l ipids  in all  three sets  of experiments testing single l ipid 
inf luence.  
1st set C12-(2-3-2) DPPC Cholesterol DMG-PEG2k 
Standard formulation 8 5.29 4.41 0.88 
No helper lipids 8 0 0 0.88 
Cholesterol low 8 0 2 0.88 
Cholesterol mid 8 0 4.41 0.88 
Cholesterol high 8 0 6 0.88 
DPPC low 8 3 0 0.88 
DPPC mid 8 5.29 0 0.88 
DPPC high 8 7 0 0.88 
2nd set     
Cholesterol low 8 0.8 2 0.88 
Cholesterol mid 8 0.8 4.41 0.88 
Cholesterol high 8 0.8 6 0.88 
DPPC low 8 3 0.8 0.88 
DPPC mid 8 5.29 0.8 0.88 
DPPC high 8 7 0.8 0.88 
3rd set     
Cholesterol low 8 2 0.8 0.24 
Cholesterol mid 8 4.41 0.8 0.24 
Cholesterol high 8 6 0.8 0.24 
DPPC low 8 0.8 3 0.24 
DPPC mid 8 0.8 5.29 0.24 
DPPC high 8 0.8 7 0.24 
 
All described formulations were characterized in terms of their physicochemical 
properties (size, zeta potential) and transfection efficiency in vitro (see Figure 3.13).  
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Figure 3.13.  The inf luence of  a s ingle helper l ipid  on transfection eff iciency in murine f ibroblasts  
(NIH 3T3) .  In  l ipoplexes in a) and b) one or both of  th e helper l ipids  were completely removed, 
whereas the amounts  of  the second were varied; in c)  and d) the am ount of one of the helper l ipids  
was kept constant,  whereas the amounts  of  the second were varied;  in  e)  and f)  the amount of  one of  
the helper l ipids  was kept constant and the amount of the PEG -lipid was reduced, whereas the 
amounts  of  the second helper l ipid were varied.   
 
The first set of experiments revealed that the formulations without DPPC were non-
functional, independently of cholesterol content (Figure 3.13a). In addition, a posi-
tive correlation between the phospholipid quantity and particle activity was ob-
served, despite lack of cholesterol in the formulation (Figure 3.13b). The efficiency 
of standard lipoplexes (marked blue in the graph) was even exceeded when more 
DPPC was incorporated in the formulation. In the second set of experiments a ten-
dency to enhanced transfection efficiency with higher amounts of DPPC was further 
confirmed (Figure 3.13d). On the contrary to the phospholipid, the variation in cho-
lesterol amount did not show a strong influence on the efficacy of protein produc-
a) b) 
c) 
e) f) 
d) 
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tion (Figure 3.13c). In the case of reduced PEG-shielding (third set of experiments), 
the trend was not as pronounced as observed for formulations with a higher PEG 
amount (first and second set), but still showing a strong correlation between high 
transfection efficiency and increased amount of a phospholipid. As shown in Figure 
3.13e, a slight increase in activity was observed with higher cholesterol content. Yet, 
the values were much lower in comparison with the standard formulation (blue 
curve). Similarly, for the formulation with varying DPPC amounts at lower PEG con-
tent, transfection rates were below the level of standard lipoplexes (Figure 3.13f). 
However, the efficiencies showed and increase compared to cholesterol formula-
tions and additionally a dependence on the DPPC amount. On the other hand, a 
general decrease resulting from lowered PEG-shielding should be noted. 
In all sets of experiments, no correlation between size, polydispersity or zeta poten-
tial of the particles and variation in the single lipid amounts was found. 
The presented results showed that the presence of a phospholipid in a formulation 
is essential for its functionality and indicated a strong correlation between the 
phospholipid amount and transfection efficiency. The effect of the second helper 
lipid, cholesterol, was less significant. In addition, the reduction in PEG-coating min-
imized the influence of a phospholipid and led to decreased efficacy.  
3.3 The importance of a PEG-lipid in lipoplex shielding 
A PEG-lipid plays a critical role in lipoplex composition as a shielding agent, enabling 
prolonged circulation in the blood and preventing undesirable interactions. There 
are a couple of variables in a PEG-lipid, which could have an influence on complex 
stability and transfection efficiency: i) a PEG lipid type (i.e. glycerolipid vs. glycer-
ophospholipid), anchor length and ii) if saturated or unsaturated, iii) as well as poly-
ethylene glycol length. Some selected comparisons of these are presented in the 
following chapter. 
3.3.1 PEG lipid type and anchor chain saturation 
As a starting point in the lipid formulation included 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) 
(DMPE-PEG2k), a PEG-lipid with two compensating charges in the backbone. The 
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first aim was to compare it with a neutral PEG-lipid widely used in nucleic acid de-
livery, 1,2-dimyristoyl-sn-glycerol, methoxypolyethylene glycol (DMG-PEG2k). 
Therefore, lipoplexes varying in one PEG-lipid type only, were tested for their trans-
fection efficiency in vitro as well as in vivo (see Figure 3.14).  
 
 
Figure 3.14.  a)  Chemical  structures of  DMPE -PEG2k and DMG-PEG2k (R=C14:0) .  Comparison of  
transfection eff iciency of  l ipoplexes comprising DMPE -PEG2k and DMG-PEG2k b) in murine f ibro-
blasts  (NIH 3T3) and c ) quantif ication of  bioluminescence intensity in treated mice .   
 
As a result, DMG-PEG2k yielded in both cases higher reporter protein levels (Figure 
3.14b-c), although its advantages over DMPE-PEG2k became significant only at low 
doses of (<62 ng/well) in vitro and showed just a tendency towards increased trans-
lation levels in vivo.  
Next, the study was extended to comparisons between: i) two neutral lipid types 
(glycerolipid and cholesterol; see Figure 15a) and ii) two different anchor chains of 
the same lipid type (glycero-3-phosphoethanolamine backbone) either saturated 
and short (C14:0) or unsaturated and long (C18:1) (see Figure 3.15b) in vitro.  
a) 
c) b) 
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Figure 3.15.  Comparison of  transfection eff iciency  in murine f ibroblasts  (NIH 3T3) of  l ipoplexes 
comprising a)  cholesterol -PEG2k and DMG -PEG2k in the formulation comprising C12 -(2-3-2)  and 
helper l ipids  cholesterol  and DOPE , b)  DOPE -PEG2k, DMPE-PEG2k, and DMG-PEG2k in  the  formulation  
comprising C12-(2-3-2) and h elper l ipids  cholesterol  and DSPC .  
  
As a result, PEGylated cholesterol did not show any benefits over DMG-PEG2k in the 
entire tested dose range (Figure 3.15a). The superior properties of DMG-PEG2k sug-
gest a significant impact of a PEG-lipid headgroup on transfection efficiency. In the 
second comparison the unsaturated anchor chain (C18:1) in 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) 
(DOPE-PEG2k) led to substantially higher efficiency than saturated and shorter an-
chor chains (C14:0) in PEGylated glycero-3-phosphoethanolamine (Figure 3.15b), 
which in turn shows the importance of the anchor chain length and saturation. 
3.3.2 Anchor chain length in a PEG-lipid 
As the next parameter, which could have an impact on lipoplex shielding, anchor 
chain length was varied. For this purpose, three saturated chains with glycerolipid 
backbone were chosen. DMG-PEG2k (R=C14:0 in Figure 3.14a) was compared with 
1,2-dipalmitoyl-sn-glycerol, methoxypolyethylene glycol (DPG-PEG2k, R=C16:0 in 
Figure 3.14a) and 1,2-distearoyl-sn-glycerol, methoxypolyethylene glycol (DSG-
PEG2k, R=C18:0 in Figure 3.14a) in the lipoplexes of the same composition for 
mRNA delivery as shown in Figure 3.16.  
a) b) 
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Figure 3.16.  Comparison of  transfection eff iciency in a) murine f ibroblasts  (NIH 3T3)  and b) mice  
after i .v .  inject ion  of  l ipoplexes comprising  PEGylated glycerol ipid with C14, C16, and C18 saturated 
anchor chains .   
 
Interestingly, a change in only 2 carbon atoms led to a markedly different transfec-
tion pattern. C16-PEG transfected cells more efficiently than C14-PEG over the en-
tire dose range, whereas C18-PEG showed high reporter protein levels only at the 
high doses with a steep drop transfection efficiency in the lower dose range as 
shown in Figure 3.16a. In vivo, six hours after i.v. injection, DPG-PEG2k showed a 4-
fold increase compared to the second best DMG-PEG2k (Figure 3.16b). The longer 
anchor chain (C18) was less efficient in mRNA delivery. 
3.3.3 PEG length 
Another parameter, which had to be taken into consideration, was the polyethylene 
glycol length in a PEG-lipid. It is known that the PEG chain length can have a signifi-
cant influence on biological activity. It has been shown that binding and uptake of 
nanoparticles by cells is affected by the PEG chain length[64]  
To understand how the PEG chain length affects mRNA delivery of lipid formula-
tions, two PEG molecular weights of 2,000 Da and 5,000 Da were compared in 
PEGylated glycerolipid of C14 and C16 anchor chains, DMG-PEG and DPG-PEG, re-
spectively, as shown in Figure 3.17. 
b) a) 
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Figure 3.17.  Comparison of  transfection eff iciency  in murine f ibroblasts  (NIH 3T3) of  l ipoplexes 
comprising DMG-PEG or DPG-PEG of  dif ferent molecular weights ,  2000 Da or 5000 Da.  
 
Although in both types of the PEG-lipids, increased PEG length inhibited cell trans-
fection, the difference between DMG-PEG 2,000 Da and 5,000 Da was not as pro-
nounced as between corresponding DPG-PEG lipids. 
In summary, the presented data show that each of the PEG-lipid characteristics, i.e. 
i) PEG-lipid type, ii) anchor length with saturated or unsaturated alkyl chains, iii) as 
well as PEG length has an impact on lipoplex activity. Taken together, this series of 
experiments allowed to identify an optimal PEG lipid anchor length and PEG molec-
ular weight. 
3.3.4 PEG-lipid density 
The shielding of the lipid complex is determined not only by the type of PEG-lipid 
and PEG-length but also by the ratio of PEGylated lipid to the other components of 
the formulation, i.e. by its total amount in the nanoparticle formulation. Increased 
PEG density was shown to affect the particle zeta potential as well as its interaction 
with cells or proteins.[65] 
In order to investigate the impact of PEG-shielding on the lipoplex properties and 
potency in mRNA delivery, a series of experiments were performed. In a first step, 
different molar percentages of DMG-PEG2k were incorporated into complexes dur-
ing the production process of either standard one-step assembling (all lipids assem-
bled at the same time) or post-assembling of excessive (in relation to the standard 
amount, 5% molar) PEG-lipid (two-step assembling: excessive PEG-lipid added to 
preassembled particles). These two mixing techniques were chosen to evaluate 
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whether coating of preassembled particles with additional PEG has an impact on 
their physicochemical properties and shielding density compared to single-step as-
sembling. The method of DMG-PEG2k post-assembling was described for siRNA de-
livery by Kumar et al.[65] The size, PDI, and zeta potential of resulting complexes are 
summarized in Table 3.4.  
Table 3.4 .  Hydrodynamic diameter,  PDI,  and zeta potential  of  l ipoplexes  with varyingDMG-PEG 
amount and method of  assembling.   
 Single-step assembling Post-assembling 
DMG-PEG2k molar     
percentage 
5% 10% 20% 5% 10% 20% 
Hydrodynamic 
diameter [nm] 
161.2 127.8 113.9 89.8 106.4 146.6 
PDI 0.144 0.221 0.236 0.195 0.240 0.162 
Zeta potential in 
water [mV] 
22.5 24.9 26.3 27.3 44.2 43.1 
Zeta potential in 
PBS [mV] 
-5.52 0.447 -3.1 -2.24 -3.39 -2.47 
 
For the single-step assembly process, increased PEG-lipid amounts did not affect 
zeta potential. On the other hand, a trend towards decreased size was observed, 
whereas polydispersity of the nanoparticles slightly increased. In the case of post-
assembled formulations, the shielding decreased at high amounts of DMG-PEG2k as 
demonstrated by the increased zeta potential (at least measured in water).Particles 
also became larger but without changes in polydispersity. 
All six complexes were tested in terms of transfection efficiency as well (see Figure 
3.18).  
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Figure 3.18.  Transfection eff iciency in murine f ibroblasts  (NIH 3T3)  of  l ipoplexes with varying DMG-
PEG amount and method of assembling; a) pre-assembled excessive PEG-lipid amount,  b) post -
assembled excessive PEG -lipid  amount .   
 
Higher percentage of incorporated DMG-PEG2k enhanced the detected protein lev-
el (Figure 3.18a) and the process of post-assembling increased this effect even fur-
ther (Figure 3.18b). Interestingly, this phenomenon was observed only for the high 
doses of mRNA. 
As the effect of PEG-shielding on particle activity may become most apparent in 
vivo, a comparison of 5% and 20% DMG-PEG2k (both pre-assembled) was per-
formed after i.v. injection in mice (Figure 3.19).  
 
Figure 3.19.  Comparison of  transfection eff iciency  in mice of  l ipoplexes comprising of  5% or 20% 
molar DMG-PEG2k.  
 
The results from the in vivo experiment (Figure 3.19) showed that lipoplexes with 
5% content of DMG-PEG2k were almost 6-fold more efficient that lipoplexes with 
20% of DMG-PEG2k. 
b) a) 
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In the second step, the PEG-lipid amount was further increased and, additionally, 
DPG-PEG2k was included in the experiment in order to examine if the observed 
trends are independent on a PEGylated glycerolipid type (Figure 3.20). 
Figure 3.20.  a)  Hydrodynamic diameter and b) polydispersity of  l ipoplexes comprising DMG -PEG2k 
or DPG-PEG2k in a varying molar amounts .   
A trend towards decreasing size (Figure 3.20a) and increasing PDI (Figure 3.20b) 
with increasing PEG-lipid amount was observed for DPG-PEG2k. In the case of DMG-
PEG, although the tendencies were not as evident, a notable increase in PDI for 40% 
of a lipid was observed. 
The observed tendencies in size and PDI were followed by appearance of a second 
peak population in the size distribution graphs, as seen in Figure 3.21. A potential 
explanation for this observation might be the existence of a subpopulation of 
~20 nm particles resulting from excessive PEG-lipid which could not be incorporated 
into complexes anymore. This would possibly lead to the formation of PEG-lipid 
micelles, which should be smaller than the major particle population comprising the 
encapsulated mRNA. To prove this hypothesis, pure DMG-PEG2k micelles were 
formed by mixing ethanol solution of the lipid with the citric buffer (just as for lipid 
nanoparticles but without mRNA) and dialyzed. Resulting particles were compared 
in terms of their size with the size distribution of lipoplexes formed with an excess 
of DMG-PEG2k (Figure 3.21; PEG-micelles in a dashed line). 
a) b) 
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Figure 3.21 .  Size distr ibution graphs by in tensity of  scattered l ight of  l ipoplexes  comprising 20% 
molar DMG-PEG2k (solid l ine)  and pure DMG-PEG2k micelles  (dashed l ine) .   
 
As the main peak from PEG-lipid micelles (Figure 3.21) appeared at the size of the 
particle subpopulation in the sample with lipoplexes comprising 20% molar DMG-
PEG2k , it was confirmed that above a certain ratio of a PEG-lipid, the excessive 
amounts of PEG-lipid are not incorporated into lipid particles anymore. 
The presence of PEG-lipid micelles could also be the reason for the observed cell 
transfection pattern (see Figure 3.18). In order to confirm this, pure DMG-PEG2k 
micelles were added to the wells of cells transfected with a standard formulation 
(containing 5% DMG-PEG2k) to a final amount of 20% DMG-PEG2k (15% in a form of 
PEG-lipid micelles). The results are presented in Figure 3.22.  
 
Figure 3.22 .  Transfection ef f iciency in murine f ibroblasts  (NIH 3T3) of  l ipoplexes with 5% DMG -
PEG2k compared with the same l ipoplexes  after addition of  DMG-PEG2k micelles .   
 
As observed in Figure 3.22, the pattern of augmented reporter enzyme activity at 
higher doses was similar compared to the transfection with formulations with high-
er PEG-lipid amount.  
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In conclusion, PEG-lipid content above 5% did not lead to increase in shielding since 
the results suggest that it could not be properly incorporated in the particle any-
more. 
3.4 Coupled dependences between the lipids 
The side by side comparisons of lipid nanoparticles varying in only one component 
(e.g. oligoalkylamine headgroup) orfactor (e.g. lipidoid alkyl chain length) help to 
understand the multicomponent system of lipid-mRNA complexes. However, more 
complex interactions, i.e. coupled dependences between two or more lipid compo-
nents, must not be omitted when optimizing lipoplex formulation.  
3.4.1 Multicomponent system interactions 
As it became apparent that transfection efficiency of a formulation comprising a 
certain individual lipid can be largely affected by the remaining lipids of the formu-
lation and their ratios (see Chapter 3.2.3 Variations in the composition), it would be 
helpful to better understand mutual interactions between the lipids in order to 
generate more general rules or trends for the design of optimized formulations. 
Since the effect of alkyl chain length was investigated in the case of lipidoids, helper 
lipids as well as PEG-lipids, the coupled interactions between alkyl chain lengths of 
different lipidic components were first analysed. For this purpose, the combinations 
of varying alkyl chains simultaneously in both (2-3-2)-based lipidoids and PEGylated 
glycerolipid were tested in vitro for their transfection efficiency, as shown in Figure 
3.23. A list of tested combinations (all contained cholesterol) is presented in Ta-
ble 3.5.  
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Table 3.5 .  A  summary of  formulation combinations with varying alkyl  chains s imultaneously in both 
(2-3-2)-based l ipidoids and PEGylated glycerolipid .  All  formulations contained cholesterol .   
(2-3-2)-based lipidoid PC helper lipid PEGylated glycerolipid 
C10 C16 C14 
C12 C16 C14 
C14 C16 C14 
C16 C16 C14 
C10 C16 C16 
C12 C16 C16 
C14 C16 C16 
C16 C16 C16 
C10 C16 C18 
C12 C16 C18 
C14 C16 C18 
C16 C16 C18 
 
 
Figure 3.23.  Transfection eff iciency of  l ipoplexes with varying alkyl  chain length in both l ipidoid 
and PEG-lipid.   
 
d) c) 
b) a) 
3 Results 
58 
 
The effect of alkyl chain in lipidoid (C10-, C12-, C14, or C16-(2-3-2)) varied in the 
presence of different alkyl chain length in PEG-lipids (C14-, C16-, or C18-PEG-lipid, 
DMG-, DPG-, and DPG-PEG2k, respectively). When combined with C14-PEG, the 
highest transfection efficiency in the tested dose range was observed for C10- and 
C12-(2-3-2), although high levels of protein translation were also observed at the 
highest dose of the C16 lipidoid formulation. With C16-PEG in the formulation, max-
imum transfection efficiencies shifted towards higher doses with increasing alkyl 
chain length of the lipidoids. In the case of C18-PEG these maxima were shifted 
even further, to 1 µg mRNA/well and higher, as seen in Figure 3.23c-d. Interestingly, 
here the efficiency of C10-(2-3-2) was much lower than for the other tested lipid-
oids with longer alkyl chains. 
It could be expected that a similar effect of mutual interactions of the alkyl chain 
lengths of the lipidoid and a phospholipid may occur, respectively. Thus, the combi-
nations of previously described C12, C14, and C16 PCs with C8-, C10-, C12-, and 
C16-(2-3-2) were tested in vitro (see Figure 3.24). A list of tested combinations (all 
contained cholesterol) is presented in Table 3.6. 
 
Table 3.6 .  A  summary of  formulation combinations with varying alkyl  chains s imultaneously in both 
(2-3-2)-based l ipidoids and helper l ipids  phosphocholines .  All  formulations contained cholesterol .  
(2-3-2)-based lipidoid PC helper lipid PEGylated glycerolipid 
C8 C12 C14 
C8 C14 C14 
C8 C16 C14 
C10 C12 C14 
C10 C14 C14 
C10 C16 C14 
C12 C12 C14 
C12 C14 C14 
C12 C16 C14 
C16 C12 C14 
C16 C14 C14 
C16 C16 C14 
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Figure 3.24.  Transfection eff iciency of  l ipoplexes with varying alkyl  chain length in both l ipid oid 
and a phospholipid  (phosphocholine).   
 
Here, in all four sets of tested combinations the lowest chain length of phosphocho-
line showed low transfection efficiency independently of the lipidoid. The ad-
vantage of C16 PC was obvious in combination with C12-(2-3-2), as shown already in 
Chapter 3.2.1.3, but became disputable in the case of lipidoids of shorter or longer 
chain lengths. To make this comparison more transparent from the perspective of a 
helper lipid, the curves of transfection efficiency of DPPC in combination with lipid-
oids of different alkyl chain length are summarized in Figure 3.25.  
 
d) c) 
b) a) 
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Figure 3.25.  Transfection eff iciency of  l ipoplexes  comprising DPPC (C16 PC) as  a helper l ipid with  
varying alkyl  chain lengths of  a l ipid oid .   
 
Whereas in this composition C8- and C16-(2-3-2) transfect less efficient, C10- and 
C12-(2-3-2) seem to be of similar activity at lower dose range, whereas C10-(2-3-2) 
exhibited a steep increase at the two highest doses tested. 
In the previous experiments the alkyl chain lengths of helper lipid (DPPC) or PEG-
lipid (DMG-PEG2k) were kept constant in the formulation. However, it would me 
more desirable to understand the interactions between all three lipid components 
of the formulation, i.e. lipidoid, helper lipid, and PEG-lipid at the same time. There-
fore, two lipidoids (C10- and C12-(2-3-2)) were combined with two helper lipids 
(C14 and C16 PCs, DMPC and DPPC) and two PEG-lipids (C14 and C16-PEG, DMG-
PEG2k and DPG-PEG2k). The list of tested combinations is summarized in Table 3.7 
and their transfection efficiency in vitro is shown in Figure 3.26.  
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Table 3.7 .  A summary of  formulation combinations with varying alky l  chains s imultaneously in 
(2-3-2)-based l ipidoids ,  helper l ipids  phosphocholines ,  and PEGylated glycerol ipid.  10-14-14 = 
C10-(2-3-2)/DMPC/DMG -PEG2k; 10-16-14 = C10-(2-3-2)/DPPC/DMG -PEG2k etc.  All  formulations 
contained cholesterol .  
Combination 
abbreviation 
(2-3-2)-based lipidoid PC helper lipid PEGylated glycerolipid 
10-14-14 C10 C14 C14 
10-16-14 C10 C16 C14 
10-14-16 C10 C14 C16 
10-16-16 C10 C16 C16 
12-14-14 C12 C14 C14 
12-16-14 C12 C16 C14 
12-14-16 C12 C14 C16 
12-16-16 C12 C16 C16 
 
Figure 3.26.  Transfection eff iciency of  all  variat ions of  two l ipid oids (C10- and C12-(2-3-2)) ,  two 
helper l ipids  (DMPC and DPPC) and two PEG-lipids  (DMG-PEG2k and DPG -PEG2k).  10-14-14 = C10-(2-
3-2)/DMPC/DMG-PEG2k; 10-16-14 = C10-(2-3-2)/DPPC/DMG-PEG2k etc.  All  l ipoplexes contain ed 
cholesterol .   
 
Interestingly, the optimal composition for both lipidoids was the one with C16 alkyl 
chains in the helper and PEG lipid, respectively. It also seemed that in the case of 
C10-(2-3-2) there was no difference between DMPC/DMG-PEG2k (C14 PC/C14-PEG) 
and DMPC/DPG-PEG2k (C14 PC/C16-PEG), which suggests a smaller impact of the 
PEG-lipid on translation efficiency. On the contrary, formulations containing 
C12-(2-3-2) and either DMPC/DMG-PEG2k (C14 PC/C14-PEG) or DPPC/DMG-PEG2k 
(C16 PC/C14-PEG) were more comparable, which suggest a greater impact of the 
PEG-lipid in this case. 
Summarizing this chapter, a series of experiments testing some combinations of 
varying chain lengths in a lipidoid, phospholipid, and a PEG-lipid revealed mutual 
a) b) 
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interactions between the lipids affecting the activity of the resulting lipoplexes. The 
data showed that a choice of the most effective component is mostly dependent on 
the other lipids used in the formulation. 
3.4.2 Nitrogen to phosphate ratio 
One of the reported critical factors which determines the complexation of mRNA 
and delivery capability of a cationic carrier is the nitrogen to phosphate ratio (N/P) 
which is a measure for the ratio of positive charge of the cationic carrier to negative 
charge of the nucleic acid. If the molar ratios between all four lipids of the formula-
tion are kept constant variation of the N/P ratio results in a change in total lipid to 
mRNA ratio. 
A starting point in this research was N/P 17, exhibiting high efficiency both in vitro 
as well as in vivo. However, the goal was to reduce this ratio as much as possible 
without any loss in resulting protein translation levels in order to minimize the total 
amount of lipid which would need to be applied. At first, an experiment was per-
formed in which the effect of the N/P ratio dependent on the mRNA dose was per-
formed (Figure 3.27). 
Figure 3.27 .  N/P ti tration on murine f ibroblasts  (NIH 3T3 ) from N/P 17 to 5 in doses of  a ) 0.25-
8 ng/well  and b) 16 -500 ng/well .   
 
The observation from the titration experiment was that higher N/P ratios exhibited 
lower transfection efficiencies at high doses, while higher transfection efficiency 
was observed at low doses (Figure 3.27a-b).  
The goal of the following in vivo experiment (Figure 3.28a) was to test whether re-
duction of N/P from 17 to 4 (a more than 4-fold decrease in lipid amount in relation 
b) a) 
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to mRNA) would allow to keep the efficiency while minimalizing the dose of the 
carrier (Figure 3.28). 
Figure 3.28.  B ioluminescence in mice treated with a) formulations of  N/P 17 or 8 ,  and b) formula-
tions of  N/P 8 or 4.  Formulations in a) and b) dif fered in a phospholipid type .   
 
Surprisingly, when N/P ratio was halved from the starting point of 17 to 8, the re-
porter enzyme activity in vivo showed a slight increase which, however, was not 
significant. On the other hand, further reduction to N/P 4 resulted in lower activity 
of the complex which was, however, also not significant. 
The presented data proved that it was possible to reduce N/P ratio of the lipid for-
mulation remarkably without any losses in its activity in vitro or in vivo. 
3.5 Formulation conditions 
3.5.1 Further condensation of mRNA by non-lipidic, cationic agents 
Another possibility to decrease the N/P ratio without a drop in efficiency could be 
incorporation of a positively charged non-lipidic component in a formulation, which 
would help to further complex mRNA. It has been described that i.e. Ca2+ enhances 
the transfection efficiency of DNA-cationic liposome complexes[66] and even milli-
molar Mg2+ concentrations are able to stabilize RNA tertiary structures.[67]  
In this chapter, Mg2+ was chosen to test the influence of an inorganic cation on 
mRNA delivery using the above described lipid system. For this purpose, magnesium 
chloride (MgCl2) was included in the aqueous mRNA solution of the formulation. 
Different N/P ratios (8, 6, 4, or 2) were tested for their transfection efficiency and 
characterized in terms of physicochemical properties of resulting particles (see Fig-
ure 3.29).  
b) a) 
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Figure 3.29.  Comparisons of  l ipoplexes of  N/P 8 ,  6 ,  4,  or 2  with and without Mg 2 +  in a) their abil ity  
to complex mRNA and b),  c)  their abil i ty to deliver reporter mRNA to the NIH 3T3 cells .   
 
Particles of N/P 8 or 6 formed in the presence of Mg2+ showed a tendency towards a 
decrease in size compared to those formed without any addition of Mg2+ cation 
(Figure 3.29a). Additionally, they were able to enhance transfection efficiency in 
vitro (Figure 3.29b). In contrast, when the N/P was lower (4 or 2), particles became 
larger and slightly less effective in mRNA delivery (Figure 3.29a and c). The ability of 
Mg2+ itself to interact with mRNA would be suggested by DLS measurements of re-
porter mRNA (“mRNA” in Figure 3.29a) compared to the same mRNA mixed with 
MgCl2 solution (“mRNA + Mg” in Figure 3.29a) as the diameter of the mRNA slightly 
decreases (35%).  
3.5.2 Impact of formulation pH on the mRNA binding 
The process of mRNA binding of the lipidic formulation is based on electrostatic 
interaction between the negatively charged nucleic acid and the cationic lipid. 
Therefore, it could be expected that the protonation level of the lipidoid and the 
mRNA may have a great impact on entrapment of mRNA, particle formation, and, 
hence, the performance of the mRNA-lipid complex. The initial assumption was that 
the aqueous mRNA solution should have rather an acidic pH to enable sufficient 
a) 
c) b) 
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attraction in the lipoplex. Therefore, the citric buffer of pH 4.5 was used in each 
experiment. In order to test this theory, lipoplexes were formed in citric buffers of 
pH i) lower than used for the standard formulation (pH 2 and 3), ii) equal to one of 
the pKa’s of the lipidoid (pH 5.2), iii) and higher than used for the standard formula-
tion (pH 6 and 7), and subsequently characterized for their size and PDI as well as 
tested in vitro (see Figure 3.30). Since it is known that mRNA is not stable in alkaline 
solutions[68], pH above 7 was not tested.  
Figure 3.30.  Comparison of  l ipoplexes form ulated in the c itric  buffer of  pH 2,  3,  4 .5 ,  5 .2,  6,  or 7 in  
their a) hydrodynamic diameter and polydispersity  and b)  transfection eff iciency on murine f ibro-
blasts  (NIH 3T3) .   
 
As seen in Figure 3.30a, the complexation process is affected at pH higher than 5.2 
(6 and 7) as the particle size and polydispersity increased. The physicochemical 
properties resulted in reduced transfection efficiency in vitro as well (Figure 3.30b). 
Interestingly, lipoplexes prepared at pH 2 also led to lower reporter protein levels 
despite proper particle size and polydispersity. The highest enzyme activity was ob-
served for the pH 4.5.  
No substantial differences could be observed in encapsulation efficiency deter-
mined by RiboGreen assay or in mRNA band intensity on agarose gel.  
In summary, these results showed that the optimization of formulation conditions, 
e.g. inclusion of inorganic ions such Mg2+ or pH of the mixing solution is critical for 
the mRNA complexation process and, hence, can affect the properties of lipid na-
noparticles.  
3.6 mRNA release assay 
The fate of a particle after intravenous injection is a series of complex interactions 
with the environment that is difficult to mimic under in vitro conditions. A typical 
b) a) 
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transfection procedure is helpful in judging whether the mRNA is able to enter the 
cell and how well it is tolerated but does not provide any information about e.g. 
stability in the blood. Therefore, a more detailed in vitro method was proposed. 
Based on a model described by Zhang et al.[69], in which the final release of siRNA 
from LNP was found to correlate with efficiency in vivo, a sequence of in vitro 
treatments was introduced for mRNA-lipid complexes as well. As shown in the Fig-
ure 3.31, the mRNA release assay included steps mimicking circulation in the blood, 
when a PEG-lipid is disassociated from a lipoplex, and an interaction with the anion-
ic lipids of endosomes in the slightly acidic pH, resulting in lipoplex disruption and 
mRNA release. The amount of released mRNA was quantified by RiboGreen assay.  
Figure 3.31.  A proposed model for the release of  s iRNA from LNP  (Zhang et al .) . [ 69 ]  Step 1: incuba-
tion of  LNP with serum at 37°C under physiological  pH; PEG – l ipid dif fuses  from LNP; Step 2: LNP -
serum mixture treated with anionic l iposomes at pH  6.0; cationic  l ipids  are protonated and electro-
statically interact and exchange l ipids  with an ionic l iposomes; Step  3: LNP membrane disruption and 
release of  s iRNA from LNP.  
 
At first, the optimal ratio of anionic liposomes (AL) to lipidoids in the lipoplexes was 
examined. Thus, a lipoplex comprising mRNA-FLuc was incubated with murine 
plasma at 37°C for 20 min and consequently, increasing amounts of AL comprising 
DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt))/DOPC (1,2-
dioleoyl-sn-glycero-3-phosphocholine)/DOPE were added. After 15 min of incuba-
tion at 37°C, mRNA release was quantified as a percentage of nucleic acid outside of 
the complex compared to the total amount. The resulting mRNA release depend-
ence on anionic lipids to lipidoid ratio (DOPS(-)/C12-(2-3-2)(+)) is presented in Fig-
ure 3.32.  
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Figure 3.32 .  mRNA release after treatment in plasma at 37°C in the presence of  anionic liposomes of 
dif ferent DOPS to C12-(2-3-2)  ratios .  mRNA release was expressed as  the percentage of  nucleic acid 
outside of  the complex compared to the total  amount .   
 
As seen in Figure 3.32, the release seemed to reach a plateau at DOPS to 
C12-(2-3-2) ratio of 4, which means that from this point on a saturation of AL mim-
icking endosomes occurred. In order to record an artificial endosomal escape as 
close to the cellular process as possible, an excessive amount of anionic lipids is 
unnecessary. On the other hand, the observed release effect should be noticeable. 
Therefore, for further experiments the chosen ratio of AL to lipidoid was 2.  
In order to find if such an assay is reliable, most of investigated particles were fur-
ther tested in vivo. Firstly, lipoplexes varying in the phospholipid (DPPC) amount 
described in Chapter 3.2.3 (“Variations in the composition”, see Figure 3.13f) with 
additionally included complex of different than standard molar ratios (named “var-
ied ratios”) as described by Love et al.[44] for siRNA delivery were compared (Figure 
3.33).  
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Figure 3.33 .  Comparison of  l ipoplexes with standard l ipid  ratios ,  ratios  described by Love et al . [ 44 ]  
(“Varied rat ios”)  and with varying DPPC/cholesterol  rat ios  a) in vitro in murine f ibroblasts  (NIH 
3T3) ,  b) in vivo in mice after intravenous injection,  and c) in mRNA release assay .   
 
Although the formulation with the standard ratio of lipid components performed 
most efficient in vitro (Figure 3.33a), it showed lower mRNA release than the formu-
lation with “varied” ratios (Figure 3.33c). Interestingly, the upward trend in lucifer-
ase activity with increasing DPPC amounts observed in vitro was completely re-
versed in the mRNA release assay. The “DPPC low” formulation leading to the high-
est mRNA release in the artificial endosome did not show any benefits in transfec-
tion efficiency in vitro. Two of the tested lipoplexes, with standard and “varied” ra-
tios were investigated in mice. Surprisingly, “varied” ratios led to 3-fold higher bio-
luminescence and showed correlation in trend rather with mRNA release assay than 
with transfection in vitro. 
Next, the same set of experiments was applied to lipoplexes with different helper 
lipids in the place of the phospholipid DPPC (see Figure 3.34).  
c) 
b) a) 
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Figure 3.34.  a)  In vitro and b) in vivo luminescence of  l ipoplexes comprising DPPC or other helper 
l ipids .  mRNA release from these particles  in c)  artif ic ial  endosome, d) plasma only,  and e) relative 
mRNA release defined as  ratio of  values from c) and d).  
 
In this case, no correlation between mRNA release in artificial endosomes (in the 
presence of AL) (Figure 3.34c) and in vivo results (Figure 3.34b) was observed. Also, 
in vivo data did not reflect in vitro pattern (Figure 3.34a). Therefore, an additional 
control was added to the release assay. Released mRNA was quantified in samples 
treated with plasma without addition of AL as in the Step 1 of the model depicted in 
Figure 3.31 (“Plasma control” in Figure 3.34d). Next, the ratio of mRNA release in 
artificial endosome (in the presence of AL) to mRNA release in plasma control 
(without AL) was calculated (“AL/plasma”, Figure 3.34e).This ratio was assumed to 
mimic the in vivo situation more reliably than simple mRNA release in the presence 
of AL. The plasma control would provide the information of mRNA amount released 
in the blood, whereas treatment with AL should indicate how much mRNA is re-
a) b) 
c) 
e) 
d) 
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leased later in the cell. Ratio of these two values, named “relative mRNA release” 
showed a correlation with bioluminescence in mice (Figure 3.34b and e). 
In the next release assay experiment two comparisons were made. Three different 
phosphocholines (16:1(cis)PC, 16:1(trans)PC, and 18:2(cis)PC) were tested in the 
lipoplexes comprising FLuc as well as three cationic lipids (C12-(2-3-2), C12-200, and 
MC3) were compared with each other in lipoplexes comprising mRNA coding for 
human erythropoietin (hEpo) As previously, the relative mRNA release was evaluat-
ed and compared with protein translation in vivo (Figure 3.35).  
Figure 3.35.  a)  Bioluminescence in mice treated wi th l ipoplexes comprising FLuc.  b ) hEpo levels  in 
mice treated with l ipoplexes comprising hEpo. c)  Relat ive mRNA release of  l ipoplexes comprising 
FLuc and three dif ferent phosphocholines  as  well  as  l ipoplexes comprising hEpo and three dif ferent 
l ipidoids .  d) Standard curves of  f luorescence of  FLuc and hEpo mRNA  evalutaed by RiboGreen assay.  
e)  Relative mRNA release of  two l ipoplexes with the same l ipidic co mposition but dif ferent mRNA 
(FLuc or hEpo) .   
 
e) d) 
c) 
b) a) 
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Both relative mRNA-FLuc release and a relative mRNA-hEpo release (Figure 3.35c) 
showed a correlation with bioluminescence and hEpo levels in mice, respectively 
(Figure 3.35a and b). However, if all complexes were compared to each other in 
mRNA release assay, one conclusion would be that in general mRNA-hEpo complex-
es were less efficient than mRNA-FLuc. In order to compare signals of different 
mRNAs obtained in the release assay, two additional tests were performed. Firstly, 
the standard curves of fluorescence for these two mRNAs were performed (Figure 
3.35d). Secondly, a side by side comparison of lipoplexes with the same lipid com-
position but comprising diverse mRNA sequences (mRNA-FLuc vs. mRNA-hEpo) in 
terms of mRNA release values was conducted (Figure 3.35e). FLuc led to higher flu-
orescent signal and relative mRNA release ratio than hEpo. The observed discrepan-
cies proved that lipoplexes comprising different mRNA transcripts cannot be com-
pared with each other in described assay.  
In summary, the presented mRNA release assay proved to be an effective indicator 
for formulation delivery efficiencies in vivo. The ratio of mRNA released in artificial 
endosomes to mRNA released in plasma (“relative mRNA release”) showed a posi-
tive correlation to reporter enzyme activity detected in mice after i.v. administra-
tion.  
3.7 Targeted delivery with folic acid 
With the goal of treating a variety of diseases with mRNA-based drugs, it is im-
portant to reach a target tissue exclusively with minimized translation in other or-
gans. Targeted delivery would be especially critical in the case of anti-cancer treat-
ment using mRNA coding for toxin described in the following chapter. For the pur-
pose of tumour growth inhibition a plant toxin isolated from Abrus precatorius, 
abrin, was chosen. Abrin is a highly potent member of the family of type II ribosome 
inactivating proteins (RIPs)[70,71] and has already shown promising anti-tumour ef-
fects in preclinical studies.[72] Folate receptor (FR) is overexpressed on the surface of 
many cancer types, which makes folic acid (FA) a desirable small molecule for anti-
cancer targeted conjugates. In the case of lipoplexes, in order to ensure that FA is 
present on the surface of lipoplex and, hence, available for the cellular receptors, it 
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was conjugated to a PEG-lipid (N-(Carbonyl-methoxy(polyethylene glycol))-1,2-
distearoyl-sn-glycero-3-phosphoethanolamine, sodium salt, 2,000 Da; DSPE-PEG2k). 
3.7.1 Folate targeting in vitro 
As an in vitro model for an FA-expressing tumour, KB cells were chosen, whereas 
NIH 3T3 served as a control. To prove that the targeted nanoparticles are taken up 
by the FR in KB cells, the transfection procedure was split into three steps: binding 
to the receptors (on ice), uptake (30 min at 37°C), and translation (24 h at 37°C after 
media change), which is described in more detail in Materials and Methods. Addi-
tionally, transfection with formulation comprising FA was performed in the pres-
ence of free FA in media for a competitive binding to the receptors. Furthermore, 
two controls for the targeted lipoplexes (comprising DSPE-PEG2k-FA) were included: 
DMG-PEG2k (standard) and DSPE-PEG2k formulation. The result of the transfection 
efficiency in both cell lines is presented in Figure 3.36. 
 
Figure 3.36 .  Folate target ing with l ipoplexes shown on a) KB cells  and b) NIH 3T3 as a control .   
 
As shown in Figure 3.36a, transfection efficiency of FA-conjugated lipidic carriers 
was drastically reduced by free FA. On the other hand, its non-targeted counterpart, 
DSPE-PEG2k formulation, hardly led to any reporter protein translation at all. To-
gether these results suggest that transfection was largely driven by a folate-
mediated process. A control formulation which was tested in previous chapters, 
DMG-PEG2k, showed higher transfection efficiency than DSPE-PEG2k without a tar-
geting moiety, which confirmed that FA is not essential for mRNA delivery into KB 
cells. However, DMG-PEG2k lipoplexes were not even nearly as effective as DSPE-
PEG2k with FA, which demonstrated advantages of receptor-mediated uptake. 
Transfection of NIH 3T3 was performed with media change after 30 min incubation 
b) a) 
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and proved benefits of standard DMG-PEG2k over FA conjugates (Figure 3.36b). All 
in all, the in vitro experiments showed promising results of FA targeted lipoplexes as 
they transfected cells which express the FR mostly by receptor-mediated uptake. 
3.7.2 Folate targeting in vivo 
To prove the concept of FA targeting in vivo as well, KB cells were injected into im-
munodeficient mice. Once tumours reached an appropriate size they were treated 
with FA-targeted lipoplexes carrying mRNA coding for A-chain of the toxin abrin 
(AA). Abrin belongs to the family of AB-toxins, which consist of a B subunit specifi-
cally binding to target cells and enabling cellular entry of the catalytic A subunit.[73] 
For the mRNA production only the A chain is used. The tumour growth during the 
treatment with a comparison to sucrose-treated group is shown in Figure 3.37. 
 
Figure 3.37 .  Tumour growth during treatment with FA -lipoplexes comprising mRNA coding for toxin 
abrin (DSPE-PEG2k-FA (AA)) with a sucrose-treated control .   
 
When the tumours reached the appropriate size (250 mm3), FA-targeted lipoplexes 
were injected directly into cancer tissue every 2-3 days. Compared to sucrose con-
trol, a trend of inhibited tumour growth was observed.  
With the purpose of in vivo targeting, formulations of DSPE-PEG2k-FA and DSPE-
PEG2k were compared in their ability to deliver reporter mRNA-FLuc to KB tumour 
bearing mice (see Figure 3.38). 
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Figure 3.38 .  Bioluminescence in KB tumours in mice treated with targeted DSPE -PEG2k-FA and non-
targeted DSPE -PEG2k l ipoplexes .   
 
Although there was no significant difference between these two groups (most likely 
due to the low number of animals), the average bioluminescence in tumours of 
mice treated with FA-targeted carriers was higher. 
In summary, these data suggest that targeted delivery with folic acid as a ligand is 
remarkably efficient in vitro by showing a receptor-mediated transfection process. 
Although the benefits of using targeted formulation in vivo were not significant, a 
trend towards increased bioluminescence in mice treated with FA-targeted lipo-
plexes was observed. Moreover, the lipid nanoparticles successfully delivered the 
therapeutic mRNA to the tumour tissue.  
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4 Discussion 
The aim of this thesis was the optimization of a multicomponent lipid-based deliv-
ery system for chemically modified mRNA. The experiments were designed to tailor 
the formulation towards the needs of mRNA and help to understand the delivery 
process with this system in more detail. The following chapter contains conclusions 
drawn from the results of the experiments and possible explanations for the obser-
vations. The contribution to the knowledge of aspects crucial for transfection pro-
cess enables further development of transcript therapies. 
4.1 Lipidoids 
A cationic lipid plays a crucial role in mRNA delivery in lipid-based systems, fulfilling 
more than just one function. Not only encapsulation of a polyanionic nucleic acid 
via electrostatic interactions, but also cellular uptake as well as endosomal escape 
of a complex are among them. Cationic particles can bind to anionic functional 
groups on a cell surface and undergo a clathrin-mediated uptake.[74] After endocy-
tosis, cationic lipids are presumed to interact with anionic phospholipids in the en-
dosomal membrane, forming ion pairs that adopt nonbilayer structures such as 
hexagonal phase (see Figure 4.2) and, hence, disrupt membranes.[20,45] 
At first, the lipidoid headgroup became the subject of the studies. A small set of 
oligoalkylamines (tri- (2-2, 3-3) and tetramines bearing ethylene (2-2-2) and/or pro-
pylene spacers (2-3-2, 3-3-3)) were modified with C12 alkyl chains and screened for 
their buffering capacity. High buffering capacity in a pH range 6.2-6.5 is hypothe-
sized to enhance endosomal escape of the mRNA-carrier complex into the cytosolic 
compartment. The assumption was based on a discovery of a strong correlation 
between carrier’s pKa in above mentioned range and in vivo siRNA activity.[21] Since 
the results showed that only C12-(2-3-2) displayed a clear peak in the desired range, 
this tetramine was expected to deliver mRNA to the cells efficiently. All tested struc-
tures, when complexed together with mRNA and three other lipids (two helper li-
pids and a PEG-lipid), formed monodisperse, spherical particles in the nanosize 
range of neutral or slightly positive zeta potential. Moreover, the encapsulation 
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efficiency was high in each case (>90%) and mRNA was shown to be intact. In con-
clusion, all nanoparticles fulfilled the physicochemical requirements of complexes 
suitable for in vivo applications. However, a careful analysis of the agarose gel (Fig-
ure 3.3) reveals that the mRNA band intensities of complexes with lipidoids bearing 
propylene spacers only (C12-(3-3) and -(3-3-3)) were slightly weaker than in other 
cases. Such an observation could indicate a very strong binding of these lipidoids to 
the nucleic acid, which is undesired and can hamper the translation process as it has 
been shown for some polymeric carriers.[26] Next, as a prerequisite for any further 
cellular processes, the particle uptake of lipoplexes was evaluated. Even though 
some differences in the kinetics of the process were observed, in general the uptake 
driven by tetramine-based lipids was on a comparable level, whereas triamine-
based lipids led to poor reporter mRNA levels in the cells. If the cellular uptake of 
lipoplexes was a limiting step of the transfection process, it should result in a similar 
transfection efficiency order like the observed uptake levels. However, the recorded 
protein translation values differed from expectations (e.g. poor transfection effi-
ciency in the case of C12-(3-3-3) despite effective uptake), which excludes the cellu-
lar uptake as the most crucial factor. Nevertheless, it could be assumed that a cer-
tain threshold needs to be exceeded. Since the good tolerability of the carriers is 
one of the most important requirements of their characteristics, the cell viability of 
the cells treated with each screened lipidoid in lipoplexes was tested. The results 
demonstrated that C12-(2-2-2) is the least toxic. However, the differences in cell 
viability also exhibited no correlation with transfection efficiency. The following 
screening for efficient delivery of mRNA in nanoparticles showed that a tetramine 
with alternating ethyl–propyl–ethyl spacers (C12-(2-3-2) exhibited a high ability to 
mediate robust levels of protein translation in vitro in four different cell lines, de-
rived from different species and tissues, although the oligoalkylamines within the 
tested carriers hardly varied. The beneficial delivery capability of the (2-3-2)-based 
lipid was further confirmed in mice. Importantly, no direct correlation between 
augmented protein levels driven by C12-(2-3-2) and particles properties, cellular 
uptake or viability was found. The main influencing parameter seems to be the 
buffering capacity in the pH range 6.2-6.5, as it was described for siRNA delivery.[21] 
The transfection with lipoplexes comprised of carriers with low buffering capacity in 
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the endosomal pH range exhibited only low levels of reporter enzyme activity in 
murine fibroblasts. In contrast, the lipidoid C12-(2-3-2), showing high buffering ca-
pacity in the pH range 6.2-6.5, exhibited superior activity compared to the other 
tested lipids. Such a result confirms the importance of protonation in the endoso-
mal escape and, hence, carrier efficiency.  
The observation of a clear advantage of the alternating oligoalkylamine-bearing 
lipid in vitro, independent of cell type, as well as in vivo indicates the existence of a 
general structural trend. The lack of functionality of triamine-based carriers could 
be hypothetically explained by the odd-even effect described by Uchida et al.[31] 
They have shown that polyplexes with odd number of repeats displayed an increase 
in efficiency compared with those with even number of repeats (PA-Es). The scaf-
folds with even number of repeats were unstable in the cytoplasm, which disabled 
them to transfect the cells efficiently. One hypothesis explaining the effect of the 
alternating structure would be that it combines good buffering capacity with suffi-
cient, but also not too strong, complex stability. As a consequence, endosomal re-
lease of (2-3-2) tetramine is facilitated and the intact complex is able to enter the 
cytosol. These surprising findings reveal that even subtle changes in the structure of 
carriers hold high potential for carrier improvements. However, a detailed investi-
gation regarding the underlying mechanism of this structure–activity relationship 
has to be the topic of further studies. 
The dendrimeric structures based on the alternating oligoalkylamine motif showed 
100-fold lower transfection efficiency in vivo compared to the initial carrier 
C12-(2-3-2). However, it is important to note that the same N/P ratio applied to 
linear G0 (2-3-2) and branched G1 or G2 leads to smaller total amounts of the lipid 
with increasing generation (G0 to G2) as the number of potentially protonable 
amines also increases (from 4 to 14). The low values of encapsulation efficiency of 
particles comprising C16-G1 and C12-G2 (23% and 49%, respectively) together with 
negative zeta potential values (-14.8 and -23.5 mV, respectively) suggest that higher 
amounts of dendrimer-based lipids would be required to obtain particles of desired 
properties. It has been shown that similar, lipid-derivatized dendrimeric structures 
possess high potency for siRNA delivery.[52] Described there dendrimer to siRNA 
ratio 5:1 (w/w) would approximately correspond to N/P ratio 10 calculated for 
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complexation of mRNA. However, such amounts might be insufficient in the case of 
mRNA due to differences in size of these two nucleic acids.  
The investigation of an alkyl chain length in lipidoids showed that neither too short 
(C5 or C6) nor too long (C16) alkyl chains are able to deliver mRNA with high effi-
ciency, both in vitro and in vivo. The optimum in the tested cell line was found with-
in C12 and C14, whereas in mice it shifted to C10 and C12. Previously, it has been 
shown that tails shorter than C12 did not exceed 30% silencing with siRNA.[44] Possi-
bly the optimum is shifted to the shorter alkyl chains in the case of mRNA, although 
it should be acknowledged that an optimized combination of a headgroup and tail 
might be more critical. 
4.2 Helper lipids 
Not only the lipidoid, but also other components in a lipid delivery system are cru-
cial for its efficiency. The results demonstrated that in the absence of a phospholip-
id, lipoplexes were completely nonfunctional in mRNA delivery, both in vitro as well 
as in vivo. Such outcome supports the theory of the charge mediator role of a phos-
pholipid: forming ion pairs between its phosphate group and lipidoid headgroup, 
whereas positively charged moiety (e.g. choline in the case of phosphocholines) 
interacts with nucleic acid phosphates.[50] Especially that the activity in vivo seemed 
to be independent on the phospholipid type (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) or 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC)). The hypothetical phospholipid role in transfection efficiency has been 
thoroughly explained on the example of DOPE or DPPE (dipalmitoylphosphatidyl-
ethanolamine) lipoplexes for oligonucleotides delivery.[75] The authors proposed 
that helper lipids promoting formation of a hexagonal phase (see Figure 4.2) also 
enhance transfection efficiency (DOPE in the described experiments). In contrast to 
lamellar phase, hexagonal conformation is critical for an efficient endosomal es-
cape, mostly in terms of complex translocation across the membrane but also of 
nucleic acid dissociation from the lipoplexes. 
In addition, although some tendencies in phospholipid chain length and saturation 
could be noted in the in vitro experiments, no pronounced effects were observed in 
vivo. 
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The influence of the second helper lipid, cholesterol, on the transfection efficiency 
in vitro was less evident than in the case of DPPC. Moreover, it could be observed in 
the formulations with lowered PEG-shielding only. The possible explanation lies in 
the presumable cholesterol role, namely stabilization of the lipoplexes.[76,77] This 
lipoplex characteristic has a greater impact on in vivo application and especially in 
well shielded particles did not lead to significant differences in transfection efficien-
cy. Moreover, some specific cholesterol-driven effects, e.g. described cholesterol 
ratio-dependent targeting of liver cells subpopulation shown for gene silencing[52] 
can be observed in vivo exclusively.  
4.3 The importance of a PEG-lipid in lipoplex shielding 
Since the role of a PEG-lipid is the most critical for in vivo applications as it prolongs 
the particles circulation in the blood stream and prevents interactions with blood 
components, it is a challenge to test its influence in cell culture. Yet, an attempt to 
determine the impact of a PEG-lipid headgroup, anchor length and saturation, PEG 
length, and PEG-lipid density in the formulation was made. At first, a couple of dif-
ferent backbones were compared in terms of their transfection efficiency. On the 
contrary to the phospholid, it does not seem to be critical for complex activity to 
use a PEG-lipid with a backbone comprising charged moieties (e.g. 1,2-dimyristoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (am-
monium salt) (DMPE-PEG2k)). On the other hand, since neutral 1,2-dimyristoyl-sn-
glycerol, methoxypolyethylene glycol (DMG-PEG2k) exhibited a trend towards in-
creased efficiency compared to DMPE-PEG2k but at the same time another neutral 
PEG-lipid (cholesterol-PEG2k) showed lower activity, the effect of a backbone must 
be much more complex.  
A more distinct effect was observed when the unsaturated and long anchor chain 
(C18:1) was compared to the saturated and short one (C14:0) in PEGylated glycero-
3-phosphoethanolamine (DOPE-PEG2k vs. DMPE-PEG2k). The results demonstrated 
higher delivery potential of the first one. However, as both anchor length and satu-
ration varied, the influencing factor could not be identified. Nonetheless, further 
experiments allowed to attribute a significant impact to the anchor length. Even 
subtle variations in the anchor chain length (from C14 to C16) showed a drastic im-
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pact on the transfection efficiency. As it has been described, the hydrophobicity of 
the PEG-lipid changes the particle deshielding rate and, hence, carriers activity.[56]  
The comparison of two different PEG lengths (2,000 and 5,000 Da) in vitro showed 
that the increased PEG chain hampers the transfection process. Such a result could 
be an indicator of higher shielding (more stealth particles obtained), especially tak-
ing into consideration the fact of slower deshielding of the particles in cell 
culture.[78] The longer PEG applied in vivo could prolong the blood circulation of the 
lipoplexes, which would lead to changes the translation kinetics. Another possible 
result could be faster recognition by the immune system. It has been shown for the 
lymph node targeting liposomes that increased PEG length accelerates the vesicle 
transport.[79] Therefore, the impact of the PEG chain length on mRNA delivery 
should be further investigated in an animal model.  
In order to obtain stealth nanoparticles, their surface should be completely covered 
with a PEG-lipid. Especially with the aim of targeted delivery, stealth particles would 
be beneficial by reducing any unspecific interactions and, hence, ensuring receptor-
mediated uptake mostly. In a series of experiments with pre- and post-assembling 
of a PEG-lipid up to 40% molar (of all lipids) it was shown that from a certain point 
saturation on the particle surface is reached. The excessive PEG-lipid cannot be in-
corporated into lipoplexes anymore, forming PEG-micelles as separate particle pop-
ulation. When the method of post-assembling was applied, the resulting particles 
exhibited size and zeta potential increase without changes in PDI. These results sug-
gest that this way of particle formation allows to incorporate larger amounts of a 
PEG-lipid than the typical one-step, pre-assembling process. The decrease of activity 
related to higher PEG-lipid content observed in vivo is most likely due to obtaining 
more stealth particles. As it has been shown for lipid nanoparticles for gene silenc-
ing, increased PEG density led to reduced efficiency in vivo due to inhibited ApoE-
mediated delivery mechanism.[65] However, the efficacy of lipoplexes with 20% PEG 
could be rescued by attaching a targeting ligand on the particle surface. 
4.4 Coupled dependences between the lipids 
In some experiments it could be noted that variations in one lipid component have 
an impact on trends observed for another one, e.g. decreased amount of a PEG-lipid 
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changes the examined single lipid dependence patterns (Chapter 3.2.3 “Variations 
in the lipid composition”). Therefore, the outcome of a screening focusing on only 
one component or moiety can be affected by the remaining lipids or their ratios. For 
that reason it is important to understand the role and impact of each variable 
(headgroups, alkyl chain length and saturation, molar ratios, N/P etc.) in the com-
plex “lipoplex equation”. However, it must be noted that these variables are not 
necessarily independent from each other. In this chapter, an attempt to define 
some rules in the influence of a lipid alkyl chain length on the transfection efficiency 
in relation to other lipid components has been made. 
Interestingly, in the experiments varying the alkyl chain lengths of the lipidoid and 
the PEG-lipid at the same time a shift in maximal efficiencies to the higher doses 
with increasing alkyl length of lipidoid was observed (see Figure 3.23). An explana-
tion could be stronger binding of mRNA with increasing alkyl chain length, which 
leads to higher effective doses. Moreover, the mutual interactions between the 
lipids revealed that a factor playing an important role is rather the length difference 
between alkyl chains of compared lipids. For instance, the highest transfection effi-
ciency for C14-PEG was obtained with C10-(2-3-2) and for C18-PEG with C14-(2-3-2) 
(in both cases length difference of four carbon atoms). On the other hand, in the 
experiment investigating the coupled dependences between alkyl chain lengths of 
the lipidoid and the phospholipid at the same time exhibited rather constant ad-
vantage of using C16 PC. Such discrepancies in the observed patterns of the coupled 
dependences lipidoid/PEG-lipid and lipidoid/phospholipid should not be unexpected 
when the different role of each lipid is taken into consideration. A variation in alkyl 
chains of lipidoid/PEG-lipid presumably determines the particles stability and mRNA 
binding strength, whereas a phospholipid supposedly has an optimal alkyl length for 
mediating the charge between mRNA and the lipidoid more independently of the 
lipidoid’s chains. In order to make the influence of varying alkyl lengths in both lip-
idoid and phospholipid at the same time more transparent, some graphs from per-
formed experiments were gathered together in Figure 4.1. The length difference of 
four carbon atoms was chosen (ΔC=4, e.g. C10-(2-3-2) and C14 PC) as it seemed 
optimal in some previously tested formulations. 
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Figure 4.1 .  Transfection eff iciency of  l ipoplexes comprising l ipidoids and phospholipids  with the 
length dif ference in alkyl  chain lengths of  four carbon atoms.  
 
As shown in Figure 4.1, the transfection efficiency indicated higher complex activity 
when both chains were shorter (C10-(2-3-2) in combination with C14 PC).  
With the addition of the third component in the evaluation of mutual interactions 
between the lipids the number of possible combinations escalates. Thus, only two 
components of each lipid type were chosen: C10- and C12-(2-3-2), C14 and C16 PC, 
as well as C14- and C16-PEG. The transfection efficiency experiment in vitro re-
vealed that for both tested lipidoids the highest activity was reached in combination 
with C16 PC and C16-PEG. In the tested range, the impact of variations in PEG-lipid 
anchors seemed to have greater impact on C12- than C10-(2-3-2) formulations. 
Another tested coupled dependence was the N/P ratio. Since it is determined by 
the proportion of a lipidoid to mRNA, variations in its value result in a change of the 
total amount of the lipids to mRNA ratio. It is necessary to find an optimal N/P ratio: 
sufficient for mRNA complexation and delivery to the cells but with minimized dose 
of applied carrier. The presented data of bioluminescence in mice after stepwise 
reduction in the N/P ratio proved that a ratio as low as 4 is sufficient for pro-
nounced reporter protein translation. Previous studies on siRNA delivery have 
shown that reducing the lipid to siRNA ratio led to only slight decrease in efficiency, 
while demonstrating significant positive effect on tolerability.[56] The optimum was 
found at lipid to siRNA ratio 7.5 (w/w), which would roughly correspond to N/P 5 in 
the case of lipid formulation for mRNA described in this work. Other siRNA lipid 
formulations use lipid to siRNA ratio ranging from 17[21] down to as low as 2.6.[69] 
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In conclusion, even very limited number of tested variables and combinations be-
tween them clearly showed that in a multicomponent delivery system results of 
side-by-side comparisons can be affected by other components or ratios in the for-
mulation. Apparently even subtle changes such as two carbon atoms in alkyl chains 
can drastically influence carriers’ activity. On the other hand, the chain saturation 
has an impact on the lipid transition temperature (the temperature at which lipid 
bilayers shift from stable lamellar phase to the less stable hexagonal phase, see Fig-
ure 4.2), which is hypothesized to enhance lipoplex escape from the endosome.[80] 
 
 
Figure 4.2 .  L ipid structures .  The mixing of  cationic (orange) and anionic (blue)  l ipids  promotes the 
transit ion from the more stable lamellar phase to the less  stable hexagonal phase,  thus aiding fusion 
of  the l iposomal and  endosomal membranes . [ 80 ]  
 
The challenge involves finding an optimum among all possibilities. However, varia-
tions in all considered influencing parameters (lipid types, alkyl chain lengths and 
saturation, linker type, ratios, mixing conditions etc.) gives a number of possible 
combinations that is unattainable to test. On the other hand, obtained data made it 
evident that testing only one variable while keeping the remaining ones constant 
reminds moving along single axis in an n-dimensional matrix: only a surface can be 
seen and many points inside of it are missed. One solution could be using an or-
thogonal array optimization, as proposed by Li et al.[81] Such an experimental design 
enables a significant efficiency improvement with reduced experimental workload. 
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4.5 Formulation conditions 
In order to decrease N/P ratio further without any reduction in delivery capability of 
lipoplexes, magnesium cations were incorporated as nonlipidic agent stabilizing the 
mRNA structure. The stabilizing properties were indicated by decreasing tendency 
in size as well as improved transfection efficiency at N/P 8 and 6 in the presence of 
Mg2+. As already proposed by Uchida et al.,[31] stability of mRNA in the cytoplasm 
correlates with sustained protein translation. Therefore, developing a system con-
sisting not only of lipids (vital for the cell entry and endosomal escape) but also an 
inorganic component stabilizing the nucleic acid in the cytoplasm could be a solu-
tion for a novel delivery system design. 
Next, the importance of the protonation level in nucleic acid binding was shown in 
an experiment with varying pH of the formulation solution. The acidic pH below or 
equal to one of the lipidoid’s pKa’s (5.2) ensured protonation level sufficient for 
proper complexation (resulting in small, monodisperse particles). Particle formation 
in solutions of pH 6 or 7 resulted in increase in both hydrodynamic diameter and 
PDI, indicating either lack or a poor level of protonation, disabling electrostatic in-
teractions with negatively charged mRNA. In the field of siRNA delivery, it is com-
mon to use buffers of pH 4 or 5 for the lipid particle formation.[21,44,45,82] 
4.6 mRNA release assay 
An in vitro method based on a model described by Zhang et al.[69] was supposed to 
mimic the series of processes that a particle injected intravenously needs to under-
go to reach its final destination. The results showed a good correlation between 
relative mRNA release and bioluminescence in mice, proving that the proposed 
model covers the most critical steps in vivo. The relative mRNA release was defined 
as the ratio between mRNA release in artificial endosomes (samples treated with 
blood plasma and anionic liposomes, respectively) to mRNA release in plasma (a 
control without anionic liposomes). A high value of relative release means that most 
of the nucleic acid is disassembled from the complexes in the cytosol (related to the 
mRNA release in artificial endosomes), with only small losses of the cargo in the 
blood stream (related to the mRNA release in plasma). Importantly, many aspects of 
the assay should be analysed carefully before drawing conclusions about formula-
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tion suitability for in vivo applications and its activity. First of all, as shown by the 
experiments, the comparison of lipoplexes carrying different mRNAs is not possible 
due to discrepancies in the detected signal coming from different transcripts. Sec-
ondly, relative release values of tested lipoplexes should not be compared without 
prior analysis of the release in artificial endosomes and release in plasma separate-
ly. Low values of both releases (in artificial endosomes and plasma) could result in 
high values of the relative release, although tested complexes are inactive in vivo 
due to the low mRNA amounts dissociated in the cells. Thirdly, especially the plas-
ma-treated sample should be observed cautiously. Particle aggregation in the pres-
ence of plasma would exclude them from in vivo application even if the relative re-
lease value is high. This step could be standardized by introducing an additional ab-
sorbance or dynamic light scattering (DLS) measurement in the assay. Such a meas-
urement would allow a quantitative evaluation of particle stability in the blood. Last 
but not least it has to be emphasized that mRNA release assay in vitro remains a 
model, which is still very simplified compared to the complex in vivo system. Thus, it 
cannot replace testing in animal models. 
4.7 Targeted delivery with folic acid 
The most effective way to ensure high, tissue (or even cell type) specific translation 
and to minimize the risk of toxic side effects is the use of targeted delivery. In this 
work, folic acid (FA) was chosen to target tumour cells, which often overexpress the 
folate receptor on their surface. The successful receptor-specific targeting has been 
shown previously on the example of FA-PEG-siRNA conjugates,[83] multifunctional 
polyplexes for siRNA delivery with FA coupled to PEG,[84] and FA-PEG-linked two-
arm oligocation structure for siRNA as well as pDNA delivery,[85] among others. 
To ensure accessibility of the small molecule for the receptors, it has been attached 
to the PEG-lipid (N-(Carbonyl-methoxy(polyethylene glycol))-1,2-distearoyl-sn-
glycero-3-phosphoethanolamine, sodium salt, 2000 Da; DSPE-PEG2k), as shown in 
Scheme 4.1.  
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Scheme 4.1.  Structure of  a PEG-lipid and folate conjugate,  DSPE -PEG2k-FA.  
 
The experiments performed in vitro on human cervix carcinoma cells (KB) showed 
an evident receptor-mediated uptake of targeted nanoparticles (comprising DSPE-
PEG2k-FA). The translation was almost entirely inhibited by competitive binding of 
free folate added to the cells. The results also revealed that the nontargeted coun-
terpart of the tested PEG-lipid (DSPE-PEG2k) is barely able to transfect these cells, 
which is another proof of folate receptor uptake of DSPE-PEG2k-FA lipoplexes. The 
huge discrepancy between translation levels driven by targeted and nontargeted 
carriers should enable very specific delivery of mRNA in vivo, exclusively to the cells 
possessing the targeted receptor. In addition, the transfection of a control cell line, 
murine fibroblasts (NIH 3T3) revealed that in this case DMG-PEG2k was significantly 
more effective than DSPE-PEG2k-FA. Such a result indicates cell type specificity of 
FA-targeted lipoplexes.  
Cancer treatment in an animal model (immunodeficient mice with subcutaneous KB 
tumours) with lipoplexes comprising mRNA coding for A-chain of the toxin abrin 
showed a tendency towards tumour growth inhibition compared to the sucrose-
treated control. The targeting ability in vivo of FA-conjugates was tested in carriers 
comprising reporter mRNA-FLuc. Interestingly, no significant difference in detected 
bioluminescence in tumours was noted. The benefits of using FA-targeted delivery 
were evident in vitro and the nontargeted DSPE-PEG2k lipoplexes seemed to be 
almost nonfunctional, therefore the similar activity pattern in vivo was expected. 
However, a couple of factors should be taken into consideration. Firstly, the target-
ed delivery plays the most important role in vivo when the drugs are applied intra-
venously and then transported into the tissue of interest by interactions with specif-
ic receptors. In this case the transportation step was omitted as the complexes were 
applied via intratumoural injection, which could be a reason for the diminished FA 
targeting effect. Secondly, the relatively high activity in tumours of lipoplexes, 
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which were rather inert in vitro could be an indicator of a different deshielding pro-
cess or rate in the tumour tissue compared to the blood stream, let alone cell cul-
ture. Thus, lipid-based systems should be optimized separately for this application. 
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5 Summary 
The development of chemically modified mRNA opens a new way towards a novel 
class of biologic therapeutics. In contrast to gene therapy, mRNA-based drugs do 
not bear the inherent risk of insertional mutagenesis. Moreover, they provide a 
transient production platform for in situ generation of the therapeutic protein due 
to the relatively short half-life of mRNA, which enables a well-controlled therapy 
with repeated dosing. Additionally, chemical modifications of RNA nucleotides have 
been shown to decrease immune responses and improve the nucleic acid stability. 
However, the direct delivery of mRNA to cells is hampered by its highly anionic 
character that prevents a passage across cell membrane unaided and the ubiqui-
tous presence of RNases. Therefore, a delivery system that is designed for the effi-
cient encapsulation of mRNA using carriers that possess effective cell penetrating 
properties is required. 
The aim of the thesis was the development of a lipid-based carrier tailored on the 
needs of the nucleic acid, which is single-stranded (in contrast to pDNA and siRNA) 
and relatively large (compared to miRNA). The multicomponent system was sup-
posed to overcome many hurdles met by the drug on its way from the intravenous 
injection to the protein translation in the target cells, namely liver cells for metabol-
ic diseases and tumour cells for anticancer therapy. By incorporation of various 
components the goal was to achieve efficient encapsulation of mRNA, protection 
from degradation and undesired interactions in the blood stream, delivery to the 
tissue of interest, effective cell penetrating properties, the endosomal escape abil-
ity, and the final release of the nucleic acid in the cytoplasm.  
At first, a small set of lipidoids was synthesized from a series of oligoalkylamines 
and subsequently characterized in terms of their buffering capacity in the range of 
pH 6.2 to 6.5, which is hypothesized to enhance endosomal escape of the carrier 
complex into the cytoplasm through membrane disruption by positively charged 
nanoparticle surface. It was found that only the alternating structure of the lipidoid 
C12-(2-3-2) (ethyl–propyl–ethyl spacers between amines) displayed a peak buffer-
ing capacity in the desired range. Even though every tested lipidoid was able to 
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complex mRNA efficiently and form decent nanoparticles, C12-(2-3-2)-based carri-
ers showed the highest transfection efficiency in different cell lines and in an animal 
model. Since no correlation between particle uptake or cytotoxicity and their mRNA 
capability was found, the crucial effect of the buffering capacity was confirmed. 
Moreover, variation in only one methylene group resulted in enhanced protein 
translation, which reveals a novel fundamental structure–activity relationship for 
the delivery of mRNA.  
Following experiments have proven the vital role of helper lipids, among others. 
Phospholipids presumably act as the charge mediators between the lipidoid and 
mRNA and thus lipoplexes lacking this component are nonfunctional. The investiga-
tion of a PEG-lipid headgroup, anchor chain length and saturation, PEG chain length, 
and PEG-lipid density on the particle surface showed that i) even slight modifica-
tions leading to changes in a PEG-lipid hydrophobicity have a huge impact on com-
plex activity, which might be caused by a changed deshielding rate, ii) increased PEG 
length or PEG-lipid density result in stealth particles, which hamper protein transla-
tion or change the translation kinetics, iii) a certain PEG-lipid density on particle 
surface cannot be exceeded, iv) the method of post-assembling allows to incorpo-
rate more PEG-lipid than the typical pre-assembling.  
A series of experiments testing some combinations of varying chain lengths in a 
lipidoid, phospholipid, and a PEG-lipid at the same time revealed mutual interac-
tions between lipids affecting the efficiency of the resulting lipoplexes. The data 
showed that a choice of the most effective component is mostly dependent on the 
other lipids or ratios between them used in the formulation.  
The developed mRNA release assay proved to be an effective indicator for predict-
ing formulations delivery efficiencies in vivo. The ratio of mRNA released in artificial 
endosomes to mRNA released in serum showed a positive correlation to reporter 
enzyme activity detected in mice after i.v. administration.  
Moreover, the concept of targeted lipid-based delivery with small molecules as lig-
ands was proven on the example of folic acid targeting on folate receptor overex-
pressing cells. Lipoplexes conjugated with folic acid on the surface performed re-
markably efficient in vitro, showing a receptor-mediated uptake. Although the ben-
efits of using targeted formulation in vivo were not significant, a trend towards in-
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creased bioluminescence in mice treated with FA-targeted lipoplexes was observed. 
Moreover, the lipid nanoparticles successfully delivered the therapeutic mRNA to 
the tumour tissue, causing toxin-driven tumour growth inhibition.  
In conclusion, this thesis demonstrates that the fine-tuning of lipid-based carriers is 
a key to augmented mRNA delivery capability. Furthermore, it was proven critical to 
consider the multicomponent system as a complex matrix and to test coupled de-
pendences instead of single lipid components or factors. Since many tested lipo-
plexes led to high reporter protein translation both in vitro as well as in vivo, this 
work provides a foundation to develop mRNA delivery systems that may have fu-
ture clinical applications.  
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7.1 Abbreviations 
AA  A-chain of the toxin abrin 
Apo  apolipoprotein 
AL  anionic liposomes 
ASGPR asialoglycoprotein receptor 
BMA  butyl methacrylate 
cDNA complementary deoxyribonucleic acid 
CFTR  Cystic Fibrosis Transmembrane Regulator 
cmRNA  chemically modified ribonucleic acid 
cps  counts per second 
DEAEMA  diethylaminoethyl methacrylate 
DePC 1,2-di-O-hexadecyl-sn-glycero-3-phosphocholine 
DLPC  1,2-dilauroyl-sn-glycero-3-phosphocholine 
DLS  dynamic light scaterring 
DMAEMA  dimethylaminoethyl methacrylate 
DMG-PEG2k/5k 1,2-Dimyristoyl-sn-glycerol-methoxy(polyethylene glycol), 
2000/5000 Da 
DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
DMPE-PEG2k  1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-
methoxy(polyethylene glycol) (ammonium salt), 2000 Da 
DNA deoxyribonucleic acid 
DOPS  1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt) 
DOPC  1,2-dioleoyl-sn-glycero-3-phosphocholine 
DOPE  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOPE-PEG2k  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
methoxy(polyethylene glycol) (ammonium salt), 2000 Da 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) 
DOTMA  N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
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DPG-PEG2k/5k 1,2-Dipalmitoyl-sn-glycerol- methoxy(polyethylene glycol), 
2000/5000 Da 
DPPC  1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
DPPE  dipalmitoylphosphatidylethanolamine 
DSG-PEG2k 1,2-distearoyl-sn-glycerol-methoxy(polyethylene glycol), 2000 Da 
DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine 
DSPE-PEG2k  N-(Carbonyl-methoxy(polyethylene glycol))-1,2-distearoyl-sn-
glycero-3-phosphoethanolamine, sodium salt, 2000 Da 
EDTA ethylenediaminetetraacetic acid 
FA folic acid 
FBS  fetal bovine serum 
FR  folate receptor 
GalNAc  N-Acetylgalactosamine 
GFP green fluorescent protein 
hBMP-2  human bone morphogenetic protein 2 
hEpo human erythropoietin 
IFN  interferon 
IL  interleukin 
i.v.  intravenous 
LNP  lipid nanoparticle 
mEpo  mouse erythropoietin 
mRNA  messenger ribonucleic acid 
N/P (ratio)  nitrogen to phosphate (ratio) 
PA-Es polyplexes with even number repeats 
PA-Os  polyplexes with odd number repeats 
PBS phosphate-based saline 
PC  phosphocholine 
PDI  polydispersity 
pDNA  plasmid deoxyribonucleic acid 
PEG  polyethylene glycol 
PEGMA  poly(ethylene glycol) methyl ether methacrylate 
PEI polyethylenimine 
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PLL  poly(L-lysine) 
P/S  penicillin/streptomycin 
qPCR  real-time polymerase chain reaction 
RLU  relative light units 
rRNA ribosomal ribonucleic acid 
RT room temperature 
SEM  standard error of the mean 
siRNA  small interfering ribonucleic acid 
SPB surfactant protein B 
TNF tumour necrosis factor 
tRNA  transfer ribonucleic acid 
 
7.2 List of lipid-based formulations 
Table 7.1 .  List  of  all  formulat ions described in experimental  part .   
 
  Lipidoid 
Helper lipid #1 
(Phospholipid) 
Helper lipid #2 
(Cholesterol) 
PEG-lipid  
Fig. 
Formulation 
name 
Type 
Molar 
ratio 
Type 
Molar 
ratio 
Type 
Molar 
ratio 
Type 
Molar 
ratio 
N/P 
ratio 
3.1 
3.3 
3.4 
3.5 
3.6 
3.7 
C12-(2-2) C12-(2-2) 8 DOPE 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
C12-(3-3) C12-(3-3) 8 DOPE 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
C12-(2-2-2) C12-(2-2-2) 8 DOPE 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
C12-(3-3-3) C12-(3-3-3) 8 DOPE 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
C12-(2-3-2) C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
3.2 C12-(2-3-2) C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
3.8 
C8-G1 C8-G1 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 10 
C12-G1 C12-G1 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 10 
C16-G1 C16-G1 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 10 
C8-G2 C8-G2 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 10 
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C12-G2 C12-G2 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 10 
C16-G2 C16-G2 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 10 
3.9 Cx-(2-3-2) 
C5-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C6-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C8-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C10-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C14-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C16-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
3.10 
C8-(2-3-2) C8-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C10-(2-3-2) C10-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C12-(2-3-2) C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 17 
C14-(2-3-2) C14-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 17 
C16-(2-3-2) C16-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 17 
3.11 
DOPE C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
DSPC C12-(2-3-2) 8 DSPC 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
Cholesterol C12-(2-3-2) 8 Chol 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 7.5 
3.12 
16:0 C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
14:0 C12-(2-3-2) 8 DMPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
12:0 C12-(2-3-2) 8 DLPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
Diether 16:0 C12-(2-3-2) 8 DePC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
18:1 C12-(2-3-2) 8 DOPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
3.13 
1st set 
Standard 
formulation 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
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No helper 
lipids 
C12-(2-3-2) 8 - - - - 
DMG-
PEG2k 
0.88 8 
Cholesterol 
low 
C12-(2-3-2) 8 - - Chol 2 
DMG-
PEG2k 
0.88 8 
Cholesterol 
mid 
C12-(2-3-2) 8 - - Chol 4.41 
DMG-
PEG2k 
0.88 8 
Cholesterol 
high 
C12-(2-3-2) 8 - - Chol 6 
DMG-
PEG2k 
0.88 8 
DPPC low C12-(2-3-2) 8 DPPC 3 - - 
DMG-
PEG2k 
0.88 8 
DPPC mid C12-(2-3-2) 8 DPPC 5.29 - - 
DMG-
PEG2k 
0.88 8 
DPPC high C12-(2-3-2) 8 DPPC 7 - - 
DMG-
PEG2k 
0.88 8 
3.13 
2nd set 
Cholesterol 
low 
C12-(2-3-2) 8 DPPC 0.8 Chol 2 
DMG-
PEG2k 
0.88 8 
Cholesterol 
mid 
C12-(2-3-2) 8 DPPC 0.8 Chol 4.41 
DMG-
PEG2k 
0.88 8 
Cholesterol 
high 
C12-(2-3-2) 8 DPPC 0.8 Chol 6 
DMG-
PEG2k 
0.88 8 
DPPC low C12-(2-3-2) 8 DPPC 3 Chol 0.8 
DMG-
PEG2k 
0.88 8 
DPPC mid C12-(2-3-2) 8 DPPC 5.29 Chol 0.8 
DMG-
PEG2k 
0.88 8 
DPPC high C12-(2-3-2) 8 DPPC 7 Chol 0.8 
DMG-
PEG2k 
0.88 8 
3.13 
3rd set 
Cholesterol 
low 
C12-(2-3-2) 8 DPPC 0.8 Chol 2 
DMG-
PEG2k 
0.24 8 
Cholesterol 
mid 
C12-(2-3-2) 8 DPPC 0.8 Chol 4.41 
DMG-
PEG2k 
0.24 8 
Cholesterol 
high 
C12-(2-3-2) 8 DPPC 0.8 Chol 6 
DMG-
PEG2k 
0.24 8 
DPPC low C12-(2-3-2) 8 DPPC 3 Chol 0.8 
DMG-
PEG2k 
0.24 8 
DPPC mid C12-(2-3-2) 8 DPPC 5.29 Chol 0.8 
DMG-
PEG2k 
0.24 8 
DPPC high C12-(2-3-2) 8 DPPC 7 Chol 0.8 
DMG-
PEG2k 
0.24 8 
3.14 
DMPE-PEG2k C12-(2-3-2) 8 DSPC 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
DMG-PEG2k C12-(2-3-2) 8 DSPC 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
3.15 
Cholesterol-
PEG2k 
C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
Chol-
PEG2k 
0.88 17 
DMG-PEG2k C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 17 
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DOPE-PEG2k C12-(2-3-2) 8 DSPC 5.29 Chol 4.41 
DOPE-
PEG2k 
0.88 17 
DMPE-PEG2k C12-(2-3-2) 8 DSPC 5.29 Chol 4.41 
DMPE-
PEG2k 
0.88 17 
3.16 
C14-PEG2k C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 17 
C16-PEG2k C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 17 
C18-PEG2k C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DSG-
PEG2k 
0.88 17 
3.17 
DMG-PEG2k C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
DPG-PEG2k C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 8 
DMG-PEG5k C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG5k 
0.88 8 
DPG-PEG5k C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DPG-
PEG5k 
0.88 8 
3.18 
5% C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
10% C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
1.97 8 
20% C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
4.42 8 
3.19 
5% C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
20% C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
4.42 8 
3.20 
10% 
DMG-PEG2k 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
1.97 8 
20% 
DMG-PEG2k 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
4.42 8 
40% 
DMG-PEG2k 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
11.8 8 
10% 
DPG-PEG2k 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DPG-
PEG2k 
1.97 8 
20% 
DPG-PEG2k 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DPG-
PEG2k 
4.42 8 
40% 
DPG-PEG2k 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DPG-
PEG2k 
11.8 8 
3.22 
Standard 
formulation 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
3.23 
C14-PEG2k 
C10-(2-3-2) 
C10-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C14-PEG2k 
C12-(2-3-2) 
C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
           
7 Appendix 
103 
 
 
C14-PEG2k 
C14-(2-3-2) 
C14-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C14-PEG2k 
C16-(2-3-2) 
C16-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C16-PEG2k 
C10-(2-3-2) 
C10-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 8 
C16-PEG2k 
C12-(2-3-2) 
C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 8 
C16-PEG2k 
C14-(2-3-2) 
C14-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 8 
C16-PEG2k 
C16-(2-3-2) 
C16-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 8 
C18-PEG2k 
C10-(2-3-2) 
C10-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DSG-
PEG2k 
0.88 8 
C18-PEG2k 
C12-(2-3-2) 
C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DSG-
PEG2k 
0.88 8 
C18-PEG2k 
C14-(2-3-2) 
C14-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DSG-
PEG2k 
0.88 8 
C18-PEG2k 
C16-(2-3-2) 
C16-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DSG-
PEG2k 
0.88 8 
3.24 
C8-(2-3-2) 
C12 PC 
C8-(2-3-2) 8 DLPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C8-(2-3-2) 
C14 PC 
C8-(2-3-2) 8 DMPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C8-(2-3-2) 
C16 PC 
C8-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C10-(2-3-2) 
C12 PC 
C10-(2-3-2) 8 DLPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C10-(2-3-2) 
C14 PC 
C10-(2-3-2) 8 DMPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C10-(2-3-2) 
C16 PC 
C10-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C12-(2-3-2) 
C12 PC 
C12-(2-3-2) 8 DLPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C12-(2-3-2) 
C14 PC 
C12-(2-3-2) 8 DMPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C12-(2-3-2) 
C16 PC 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C16-(2-3-2) 
C12 PC 
C16-(2-3-2) 8 DLPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C16-(2-3-2) 
C14 PC 
C16-(2-3-2) 8 DMPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C16-(2-3-2) 
C14 PC 
C16-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
3.25 
C16 PC 
C8-(2-3-2) 
C8-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
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C16 PC 
C10-(2-3-2) 
C10-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C16 PC 
C12-(2-3-2) 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C16 PC 
C16-(2-3-2) 
C16-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
3.26 
10-14-14 C10-(2-3-2) 8 DMPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
10-16-14 C10-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
10-14-16 C10-(2-3-2) 8 DMPC 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 8 
10-16-16 C10-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 8 
12-14-14 C12-(2-3-2) 8 DMPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
12-16-14 C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
12-14-16 C12-(2-3-2) 8 DMPC 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 8 
12-16-16 C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DPG-
PEG2k 
0.88 8 
3.27 N/P 5-17 C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 5-17 
3.28a N/P 17 or 8 C12-(2-3-2) 8 DOPE 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 17 or 8 
3.28b N/P 8 or 4 C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 or 4 
3.29 
N/P 2-8 
+ or – Mg2+ 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 2-8 
3.30 pH 2.0 - 7.0 C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
3.33 
Standard 
ratios 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
Different 
ratios 
C12-(2-3-2) 50 DPPC 10 Chol 38.5 
DMG-
PEG2k 
1.5 8 
DPPC low C12-(2-3-2) 8 DPPC 3 Chol 0.8 
DMG-
PEG2k 
0.24 8 
DPPC mid C12-(2-3-2) 8 DPPC 5.29 Chol 0.8 
DMG-
PEG2k 
0.24 8 
DPPC high C12-(2-3-2) 8 DPPC 7 Chol 0.8 
DMG-
PEG2k 
0.24 8 
3.34 
DPPC C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
16:0 TAP C12-(2-3-2) 8 16:0 TAP 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
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16:0 DG C12-(2-3-2) 8 16:0 DG 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
16:0 EPC C12-(2-3-2) 8 16:0 EPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
16:0 DAP C12-(2-3-2) 8 16:0 DAP 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
3.35 
16:1(cis)PC C12-(2-3-2) 8 
16:1(cis) 
PC 
5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
16:1(trans)PC C12-(2-3-2) 8 
16:1 
(trans)PC 
5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
18:2(cis)PC C12-(2-3-2) 8 
18:2(cis) 
PC 
5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C12-(2-3-2) C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
C12-200 C12-200 40 DOPE 30 Chol 25 
DMG-
PEG2k 
5 15 
MC3 MC3 50 DSPC 10 Chol 38.5 
DMG-
PEG2k 
1.5 10 
3.36 
3.38 
DMG-PEG2k C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DMG-
PEG2k 
0.88 8 
DSPE-PEG2k C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DSPE-
PEG2k 
0.88 8 
DSPE-PEG2k-
FA 
C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DSPE-
PEG2k-FA 
0.88 8 
3.37 FA-Tox(AA) C12-(2-3-2) 8 DPPC 5.29 Chol 4.41 
DSPE-
PEG2k-FA 
0.88 8 
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Rudolph C., and Plank C. (pending). cmRNA/lipoplex encapsulation in PLGA micro-
spheres enables transfection via calcium phosphate cement (CPC)/PLGA composites 
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Szczególne podziękowania należą się mojej Rodzinie. Bez wsparcia moich Rodziców 
i Rodzeństwa nie byłoby mnie tutaj, gdzie jestem.  
